463 results on '"David C. Whitcomb"'
Search Results
2. Severe Pain in Chronic Pancreatitis Patients: Considering Mental Health and Associated Genetic Factors
- Author
-
Jami L. Saloman, Anna E. Phillips, David C. Whitcomb, and Ellyn K Dunbar
- Subjects
medicine.medical_specialty ,pancreatitis ,Context (language use) ,Review ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,030202 anesthesiology ,Internal medicine ,medicine ,Severe pain ,Depression (differential diagnoses) ,business.industry ,genetic research ,medicine.disease ,Mental health ,Clinical trial ,Anesthesiology and Pain Medicine ,pain management ,depression ,Anxiety ,Pancreatitis ,medicine.symptom ,business ,mental health ,030217 neurology & neurosurgery - Abstract
Pain is the most distressing and disruptive feature of recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) resulting in low quality of life (QOL) and disabilities. There is no single, characteristic pain pattern in patients with RAP and CP. Abdominal imaging features of CP accurately reflect morphologic features but they do not correlate with pain. Pain is the major driver of poor quality of life (QOL) and it is the constant pain, rather than intermittent pain that drives poor QOL. Furthermore, the most severe constant pain experience in CP is also a complex condition. The ability to target the etiopathogenesis of severe pain requires new methods to detect the exact pain mechanisms in an individual at cellular, tissue, system and psychiatric levels. In patients with complex and severe disease, it is likely that multiple overlapping mechanisms are simultaneously driving pain, anxiety and depression. Quantitative sensory testing (QST) shows promise in detecting alterations in central processing of pain signals and to classify patients for mechanistic and therapeutic studies. New genetic research suggests that genetic loci for severe pain in CP overlap with genetic loci for depression and other psychiatric disorders, providing additional insights and therapeutic targets for individual patients with severe CP pain. Well-designed clinical trials that integrate clinical features, QST, genetics and psychological assessments with targeted treatment and assessment of responses are required for a quantum leap forward. A better understanding of the context and mechanisms contributing to severe pain experiences in individual patients is predicted to lead to better therapies and quality of life.
- Published
- 2021
3. Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1/3 reduction in T-cells
- Author
-
Shikhar Uttam, E. Jeffrey Metter, Rhonda M. Brand, Aaron Siegel, David G. Binion, Jarret Engstrom, Ian McGowan, Marc Schwartz, Randall E. Brand, Ashley Zyhowski, David C. Whitcomb, Nabanita Biswas, and Beverley A. Moore
- Subjects
STAT3 Transcription Factor ,Physiology ,T-Lymphocytes ,Proinflammatory cytokine ,Piperidines ,Physiology (medical) ,Healthy volunteers ,Biopsy ,medicine ,Humans ,Intestinal Mucosa ,Protein Kinase Inhibitors ,Janus Kinases ,Tofacitinib ,Hepatology ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,JAK-STAT signaling pathway ,Bayes Theorem ,medicine.disease ,Ulcerative colitis ,Pyrimidines ,STAT1 Transcription Factor ,Gene Expression Regulation ,Immunology ,Cytokines ,Biomarker (medicine) ,Colitis, Ulcerative ,business ,Biomarkers ,Research Article ,Explant culture - Abstract
Poor translatability of animal disease models has hampered the development of new inflammatory bowel disorder (IBD) therapeutics. We describe a preclinical, ex vivo system using freshly obtained and well-characterized human colorectal tissue from patients with ulcerative colitis (UC) and healthy control (HC) participants to test potential therapeutics for efficacy and target engagement, using the JAK/STAT inhibitor tofacitinib (TOFA) as a model therapeutic. Colorectal biopsies from HC participants and patients with UC were cultured and stimulated with multiple mitogens ± TOFA. Soluble biomarkers were detected using a 29-analyte multiplex ELISA. Target engagement in CD3(+)CD4(+) and CD3(+)CD8(+) T-cells was determined by flow cytometry in peripheral blood mononuclear cells (PBMCs) and isolated mucosal mononuclear cells (MMCs) following the activation of STAT1/3 phosphorylation. Data were analyzed using linear mixed-effects modeling, t test, and analysis of variance. Biomarker selection was performed using penalized and Bayesian logistic regression modeling, with results visualized using uniform manifold approximation and projection. Under baseline conditions, 27 of 29 biomarkers from patients with UC were increased versus HC participants. Explant stimulation increased biomarker release magnitude, expanding the dynamic range for efficacy and target engagement studies. Logistic regression analyses identified the most representative UC baseline and stimulated biomarkers. TOFA inhibited biomarkers dependent on JAK/STAT signaling. STAT1/3 phosphorylation in T-cells revealed compartmental differences between PBMCs and MMCs. Immunogen stimulation increases biomarker release in similar patterns for HC participants and patients with UC, while enhancing the dynamic range for pharmacological effects. This work demonstrates the power of ex vivo human colorectal tissue as preclinical tools for evaluating target engagement and downstream effects of new IBD therapeutic agents. NEW & NOTEWORTHY Using colorectal biopsy material from healthy volunteers and patients with clinically defined IBD supports translational research by informing the evaluation of therapeutic efficacy and target engagement for the development of new therapeutic entities. Combining experimental readouts from intact and dissociated tissue enhances our understanding of the tissue-resident immune system that contribute to disease pathology. Bayesian logistic regression modeling is an effective tool for predicting ex vivo explant biomarker release patterns.
- Published
- 2021
4. Response to Liu et al
- Author
-
David C. Whitcomb and Ellyn K Dunbar
- Subjects
Stress Disorders, Post-Traumatic ,Pancreatitis ,Hepatology ,business.industry ,Gastroenterology ,Humans ,Pain ,Medicine ,Anxiety ,business ,Anxiety Disorders ,Humanities ,Article - Published
- 2021
5. Differences in Age at Onset of Symptoms, and Effects of Genetic Variants, in Patients With Early vs Late-Onset Idiopathic Chronic Pancreatitis in a North American Cohort
- Author
-
Randall E. Brand, Michelle A. Anderson, Gregory A. Cote, Adam Slivka, Bimaljit S. Sandhu, Gong Tang, Samer Alkaade, C. Mel Wilcox, Chris E. Forsmark, Stephen T. Amann, Andres Gelrud, Stuart Sherman, Dhiraj Yadav, Darwin L. Conwell, Nalini M. Guda, David C. Whitcomb, Timothy B. Gardner, Thiruvengadam Muniraj, Michele D. Lewis, Jyothsna Talluri, Jessica LaRusch, Judah Abberbock, Peter A. Banks, and Joseph Romagnuolo
- Subjects
Adult ,medicine.medical_specialty ,Idiopathic chronic pancreatitis ,Late onset ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Interquartile range ,Pancreatitis, Chronic ,Internal medicine ,medicine ,Humans ,Trypsin ,Prospective Studies ,Age of Onset ,Risk factor ,Child ,Prospective cohort study ,integumentary system ,Hepatology ,business.industry ,musculoskeletal, neural, and ocular physiology ,Gastroenterology ,Middle Aged ,medicine.disease ,humanities ,nervous system diseases ,Cross-Sectional Studies ,Trypsin Inhibitor, Kazal Pancreatic ,030220 oncology & carcinogenesis ,North America ,Cohort ,Acute pancreatitis ,Pancreatitis ,030211 gastroenterology & hepatology ,business - Abstract
Background & Aims Idiopathic chronic pancreatitis (ICP) is the second most common subtype of CP. In 1994, researchers reported the bimodal age at onset of ICP symptoms: early onset ICP (EO-ICP; median age, 19.2 y) and late-onset ICP (LO-ICP; median age, 56.2 y). Ages of onset and clinical features of ICP differed from those of alcohol-related CP (ACP). However, variants in PRSS1 had not yet been associated with ICP. We reexamined ages of onset of ICP in a large, North American cohort of patients, and investigated the effects of genetic factors and alcohol use in patients with EO-ICP, LO-ICP, and ACP. Methods We performed a cross-sectional analysis of patients with CP of European ancestry enrolled in the North American Pancreatitis Study 2, a prospective study of 1195 patients with CP from 26 centers in the United States from August 2000 through December 2014. We compared age at onset of symptoms for 130 patients with CP who were lifetime abstainers from alcohol (61 patients with early onset and 69 patients with late onset), 308 light to moderate alcohol drinkers with CP, and 225 patients with ACP and heavy to very heavy alcohol use. DNA from available patients was analyzed for variants associated with CP in SPINK1, CFTR, and CTRC. The Kruskal–Wallis test was used to compare continuous variables across groups and based on genetic variants. Results Median ages at onset of symptoms were 20 years for patients with EO-ICP and no alcohol use, 58 years for patients with LO-ICP and no alcohol use, 47 years for light to moderate alcohol drinkers with CP, and 44 years for patients with ACP. A higher proportion of patients with EO-ICP had constant pain (65%) than patients with LO-ICP (31%) (P = .04). A higher proportion of patients with ACP had pseudocysts (43%) than patients with EO-ICP (11%) (P = .001). A higher proportion of patients with EO-ICP had pathogenic variants in SPINK1, CFTR, or CTRC (49%) than patients with LO-ICP (23%), light to moderate alcohol drinking with CP (26%), or ACP (23%) (P = .001). Among patients with variants in SPINK1, those with EO-ICP had onset of symptoms at a median age of 12 years, and light to moderate alcohol drinkers with CP had an age at onset of 24 years. Among patients with variants in CFTR, light to moderate alcohol drinkers had an age at onset of symptoms of 41 years, but this variant did not affect age at onset of EO-ICP or ACP. Conclusions We confirmed previously reported ages at onset of symptoms for EO-ICP and LO-ICP in a North American cohort. We found differences in clinical features among patients with EO-ICP, LO-ICP, and ACP. Almost half of patients with EO-ICP have genetic variants associated with CP, compared with approximately one quarter of patients with LO-CP or ACP. Genetic variants affect ages at onset of symptoms in some groups.
- Published
- 2021
6. Divergent trends in lifetime drinking and smoking between Black and White Americans diagnosed with chronic pancreatitis
- Author
-
Dhiraj Yadav, Vikesh K. Singh, C. Mel Wilcox, Robert G. Feldman, Adam Slivka, Samer Alkaade, David C. Whitcomb, Nalini M. Guda, Randall E. Brand, Felicity J. Pendergast, Bimaljit S. Sandhu, and Christie Y. Jeon
- Subjects
Adult ,Alcohol Drinking ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,White People ,Article ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Pancreatitis, Chronic ,medicine ,Humans ,In patient ,Longitudinal Studies ,White (horse) ,Hepatology ,business.industry ,Smoking ,Gastroenterology ,medicine.disease ,Health equity ,Black or African American ,030220 oncology & carcinogenesis ,Etiology ,Pancreatitis ,Smoking cessation ,030211 gastroenterology & hepatology ,Lifetime Drinking History ,business ,Alcohol Abstinence ,Demography - Abstract
BACKGROUND/OBJECTIVES: Black Americans are at increased risk of chronic pancreatitis (CP) compared to their White counterparts. We aimed to describe the race-specific smoking history and lifetime drinking in patients diagnosed with CP. METHODS: We analyzed data on 334 Black and White CP participants of the North American Pancreatitis Study 2 Continuation and Validation Study and Ancillary Study. Lifetime drinking history and lifetime smoking history were collected through in-person interviews. Intensity, frequency, duration and current status of drinking and smoking were compared between Black and White CP participants, stratified by physician-defined alcohol etiology. In addition, drinking levels at each successive decades in life (20s, 30s, 40s) were compared by race and graphically portrayed as heat diagrams. RESULTS: Among patients with alcoholic CP, current smoking levels were not different by race (67-70%), but a smaller proportion of Black patients reported having smoked 1 or more packs per day in the past (32%) as compared to White patients (58%, p
- Published
- 2020
7. Severe acute pancreatitis: capillary permeability model linking systemic inflammation to multiorgan failure
- Author
-
David C. Whitcomb, Nicole L Komara, Cameron R. Breze, Georgios I. Papachristou, Anette S Wilson, Phil J. Greer, and Pedram Paragomi
- Subjects
Adult ,Male ,medicine.medical_specialty ,Physiology ,Multiple Organ Failure ,Hypovolemia ,Vascular permeability ,Systemic inflammation ,Models, Biological ,Gastroenterology ,Blood Urea Nitrogen ,Capillary Permeability ,Necrosis ,hemic and lymphatic diseases ,Physiology (medical) ,Internal medicine ,Humans ,Medicine ,Serum Albumin ,Aged ,Hepatology ,business.industry ,fungi ,Blood Proteins ,Body Fluid Compartments ,Middle Aged ,medicine.disease ,Multiorgan failure ,Systemic Inflammatory Response Syndrome ,digestive system diseases ,Systemic inflammatory response syndrome ,Hematocrit ,Pancreatitis ,Acute Disease ,Acute pancreatitis ,Female ,Hypotension ,Pancreatic injury ,medicine.symptom ,business ,Multiple organ dysfunction syndrome ,Capillary Leak Syndrome ,Research Article - Abstract
Severe acute pancreatitis (SAP) includes persistent systemic inflammation (SIRS) and multiorgan failure (MOF). The mechanism of transition from SIRS to MOF is unclear. We developed a fluid compartment model and used clinical data to test predictions. The model includes vascular, interstitial and “third-space” compartments with variable permeability of plasma proteins at the capillaries. Consented patients from University of Pittsburgh Medical Center Presbyterian Hospital were studied. Preadmission and daily hematocrit (HCT), blood urea nitrogen (BUN), creatine (Cr), albumin (Alb), and total protein (TP) were collected, and nonalbumin plasma protein (NAPP = TP minus the Alb) was calculated. Subjects served as their own controls for trajectory analysis. Of 57 SAP subjects, 18 developed MOF (5 died), and 39 were non-MOF (0 died). Compared with preadmission levels, admission HCT increased in MOF +5.00 [25%-75% interquartile range, IQR] versus non-MOF −0.10 [−1.55, 1.40] (P < 0.002) with HCT > +3 distinguishing MOF from non-MOF (odds ratio 17.7, P = 0.014). Preadmission Alb fell faster in MOF than non-MOF (P < 0.01). By day 2, TP and NAPP dropped in MOF but not non-MOF (P < 0.001). BUN and Cr levels increased in MOF (P = 0.001), but BUN-to-Cr ratios remained constant. Pancreatic necrosis was more common in MOF (56%) than non-MOF (23%). Changing capillary permeability to allow loss of NAPP in this model predicts loss of plasma oncotic pressure and reduced vascular volume, hypotension with prerenal azotemia and acute kidney dysfunction, pancreas necrosis, and pulmonary edema from capillary leak in the lung with acute respiratory distress syndrome. Sequential biomarker analysis in humans with or without MOF is consistent with this model. This study is registered on https://clinicaltrials.gov at NCT03075605. NEW & NOTEWORTHY Acute pancreatitis is a sudden inflammatory response to pancreatic injury that may spread to systemic inflammation, multiorgan failure, and death in some patients. With the use of the predictions of a new mechanistic model, we compared patients with severe acute pancreatitis with or without multiorgan failure. All biomarkers of capillary leak and clinical features of multiorgan failure were accurately predicted. This provides a new paradigm for understanding and developing new treatments for patients with severe acute pancreatitis.
- Published
- 2020
8. Low serum trypsinogen levels in chronic pancreatitis: Correlation with parenchymal loss, exocrine pancreatic insufficiency, and diabetes but not CT-based cambridge severity scores for fibrosis
- Author
-
Vikesh K. Singh, Bimaljit S. Sandhu, Venkata S. Akshintala, Samer Alkaade, Wei Zhan, Randall E. Brand, Michelle A. Anderson, Thiruvengadam Muniraj, Phil J. Greer, David C. Whitcomb, Julia B. Greer, Melena D. Bellin, Adam Slivka, Dhiraj Yadav, C. Mel Wilcox, and Georgios I. Papachristou
- Subjects
Adult ,Male ,medicine.medical_specialty ,Trypsinogen ,Endocrinology, Diabetes and Metabolism ,Pancreatic stellate cell ,Acinar Cells ,Severity of Illness Index ,digestive system ,Gastroenterology ,Cohort Studies ,Diabetes Complications ,chemistry.chemical_compound ,Fibrosis ,Pancreatitis, Chronic ,Surveys and Questionnaires ,Diabetes mellitus ,Internal medicine ,medicine ,Acinar cell ,Humans ,Exocrine pancreatic insufficiency ,Pancreas ,Aged ,Hepatology ,business.industry ,Pancreatic Ducts ,Calcinosis ,Middle Aged ,medicine.disease ,digestive system diseases ,medicine.anatomical_structure ,chemistry ,Pancreatitis ,Exocrine Pancreatic Insufficiency ,Female ,Atrophy ,Tomography, X-Ray Computed ,business ,Biomarkers - Abstract
Chronic pancreatitis (CP) is a complex inflammatory disorder of the pancreas affecting acinar cells, duct cells, islet cells and inflammatory cells including fibrosis-producing stellate cells. Serum trypsinogen is a biomarkers of acinar cell function.To define the degree of correlation between low trypsinogen levels as a marker of acinar cell function and variable features of CP.Serum samples from previously ascertained and well phenotyped case and control subjects from the North American Pancreatitis Study II (NAPS2) were used to measure serum trypsinogen levels in a commercial laboratory. Control samples were used to define normal ranges and compared with levels in CP patients with defined features.A final cohort of 279 CP patients and 262 controls from the NAPS2 studies were evaluated. In controls trypsinogen had a mean of 34.96 ng/ml and SD = 11.99. Cut-off values for low trypsinogen ranged from20 to 10 ng/ml and very low trypsinogen at10 ng/ml. Compared to controls, CP was associated with very low trypsinogen levels (p 0.0001). Within CP, very low trypsinogen levels correlated with parenchymal loss (pancreatic surgery [p 0.05]; atrophy with calcifications, [p 0.001]), EPI (p 0.01, trend p 0.001) and diabetes (trend p 0.01) but not CT-based criteria for fibrosis (pancreatic duct dilation, irregularity, strictures).Very low serum trypsinogen levels correlate with measures of acinar cell loss including surgical resection, atrophic-calcific CP, diabetes and functional symptoms EPI but not duct morphology criteria. Serum trypsinogen levels correlate with decreased acinar cell function and therefore have biomarker utility clinical management.
- Published
- 2020
9. Impact of hereditary pancreatitis on patients and their families
- Author
-
Robin E. Grubs, David C. Whitcomb, Dhiraj Yadav, Celeste Shelton, and Chandraprakash Umapathy
- Subjects
Adult ,Male ,Heterozygote ,media_common.quotation_subject ,Genetic counseling ,Genetic Counseling ,Penetrance ,Article ,Young Adult ,Pancreatitis, Chronic ,Humans ,Medicine ,Trypsin ,Family history ,Medical History Taking ,Genetics (clinical) ,Aged ,media_common ,Aged, 80 and over ,Hereditary pancreatitis ,business.industry ,Addiction ,Autosomal dominant trait ,Middle Aged ,medicine.disease ,Mutation ,Pancreatitis ,Female ,Worry ,business ,Psychosocial ,Clinical psychology - Abstract
Hereditary pancreatitis (HP), a highly penetrant (~80%) autosomal dominant disease associated with PRSS1 variants, causes acute pancreatitis in childhood and chronic pancreatitis by early adulthood. Other clinical features include pain, diabetes, and risk of pancreatic cancer. HP kindreds were prospectively recruited from 1995 to 2015. At enrollment, study participants completed medical and family history questionnaires, and provided samples for genotyping. Participants were recontacted between 2015 and 2017 and asked to complete a survey on concerns and experiences related to HP, PRSS1 testing, and genetic counseling. Data were analyzed with descriptive and thematic methods. Thirty-nine affected participants with HP and 21 unaffected family members completed the survey. Among unaffected family members, 'worry' and 'helplessness' were frequently described as the most difficult problem in their family because of HP, particularly with regard to pain. Three participants described the impact of drug addiction on their family. 'School or work limitations' was the leading financial concern, with 65.5% (36/55) rating it as 'moderately' or 'extremely important.' Unexpectedly, only 62% (21/34) of affected PRSS1 carriers believed the chance for a parent to pass HP to his or her children was 50%, whereas 18% (6/34) believed the chance was 100%. The impact of HP on individuals and families varied, which may reflect the highly unpredictable nature of HP severity and outcomes. Based on current and previously reported findings, an overview of important issues for genetic counselors to consider for counseling HP families is included.
- Published
- 2020
10. Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer: A pilot study of these conditions with and without diabetes
- Author
-
Savitri Appana, Walter G. Park, Dhiraj Yadav, Liang Li, Kimberly Stello, Steven J. Hughes, Aida Habtezion, Dana K. Andersen, Randall E. Brand, Wei Wei, and David C. Whitcomb
- Subjects
Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Recurrent acute pancreatitis ,Pilot Projects ,Gastroenterology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Recurrence ,Internal medicine ,Diabetes mellitus ,Pancreatic cancer ,Humans ,Medicine ,Aged ,Hepatology ,business.industry ,Area under the curve ,Middle Aged ,medicine.disease ,Pancreatic Neoplasms ,Gene Expression Regulation ,Pancreatitis ,030220 oncology & carcinogenesis ,Cohort ,Cytokines ,Adenocarcinoma ,Female ,030211 gastroenterology & hepatology ,business ,Biomarkers - Abstract
Objective This exploratory study seeks to identify distinct circulating immune signatures among patients having recurrent acute pancreatitis (RAP), chronic pancreatitis (CP), and pancreatic adenocarcinoma (PDAC). Methods A retrospective analysis of human serum samples from collaborating institutions of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) was performed. Samples came from the North American Pancreatitis Studies 2 (NAPS2) cohort and the Pancreatic Adenocarcinoma Gene Environment Risk Study (PAGER) and were analyzed using a 62-plex Luminex assay in a blinded fashion. Group and pairwise comparisons were performed to identify unique immune signature panels and to calculate diagnostic utility using area under the curve analysis. Results A total of 179 patients’ samples were included: 41 controls, 40 CP, 78 PDAC and 20 RAP patients, of which 20 controls, 20 CP, and 58 PDAC patients had diabetes mellitus (DM). A unique immune signature panel could discriminate RAP, CP, and PDAC from controls with an AUC range from 0.77 to 0.86 (95% CI range: 0.64–0.94), RAP from CP, and CP from PDAC with an AUC of 0.77 (95% CI 0.64–0.90) and 0.76 (95% CI 0.67–0.86), respectively. Furthermore, an immune signature panel could also discriminate PDAC-DM from DM controls with an AUC of 0.96 (95% CI: 0.93–1.00) Conclusion This study identifies unique immune analytes that may serve as novel diagnostic and predictive non-invasive biomarkers of RAP, CP, and PDAC. Further validation is warranted in prospective cohorts as developed by the CPDPC.
- Published
- 2020
11. Computed tomography based scoring system in a prospectively ascertained cohort of patients with chronic pancreatitis
- Author
-
Tang Gong, Kishore Vipperla, Anil K. Dasyam, Adam Slivka, Georgios I. Papachristou, David C. Whitcomb, and Dhiraj Yadav
- Subjects
Adult ,Male ,medicine.medical_specialty ,Scoring system ,Endocrinology, Diabetes and Metabolism ,Computed tomography ,Article ,Cohort Studies ,Atrophy ,Pancreatitis, Chronic ,medicine ,Humans ,Prospective cohort study ,Pancreas ,Pancreatic calcification ,Aged ,Pancreatic duct ,Hepatology ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Cohort ,Pancreatitis ,Female ,Radiology ,Tomography, X-Ray Computed ,business - Abstract
Objective No standardized system is currently used to report the presence or severity of parenchymal and ductal features of chronic pancreatitis (CP) on CT scan. We report a modification to the previously proposed Cambridge classification to serve this purpose. Methods Contrast-enhanced CT scans of 158 well-phenotyped patients with CP enrolled in the North American Pancreatitis Studies (NAPS2) during 2000–2014 from the University of Pittsburgh were retrospectively reviewed by a subspecialty trained abdominal radiologist. Presence and severity (score scale 0–4) of pancreatic duct (PD) dilation, obstruction and contour irregularity, pancreatic calcifications, atrophy and extent of pancreatic involvement were recorded to grade the morphological severity of CP and stratify patients into distinct morphologic patterns. Findings were also correlated with clinical features. Results Pancreatic atrophy, calcifications, PD dilation and PD irregularity were observed in 80%, 68%, 65%, 58% cases, respectively. An obstructive stone or PD stricture was present in 63%, and 86% had diffuse pancreatic involvement. Using these features, CP was noted to be moderate or severe in 61%, and classified morphologically as obstructive with/without calcifications, calcific but non-obstructive and non-calcific/non-obstructive in 65%, 20%, 15%, respectively. Functional abnormalities but not the presence of pain generally correlated with imaging findings. Conclusion A structured scoring system can provide qualitative and quantitative assessment of imaging findings in CP and an opportunity for adoption into clinical practice and research for initial evaluation and longitudinal follow-up. Our findings need validation in a prospective cohort before widespread adoption.
- Published
- 2019
12. Autoimmunity May Explain Diabetes in a Subset of Patients With Recurrent Acute and Chronic Pancreatitis: A Pilot Study
- Author
-
Dhiraj Yadav, David C. Whitcomb, Gong Tang, Adam Slivka, Melena Bellin, Samer AlKaade, Stephen T. Amann, Michelle A. Anderson, Peter Banks, Darwin Conwell, Randall E. Brand, Gregory A. Cote, Joseph Romagnuolo, Christopher E. Forsmark, Timothy Gardner, Andres Gelrud, Nalini Guda, Michele Lewis, Thiruvengadam Muniraj, Bimaljit S. Sandhu, Stuart Sherman, Vikesh Singh, and C. Mel Wilcox
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,Autoantibody ,Recurrent acute ,medicine.disease ,medicine.disease_cause ,Autoimmunity ,Internal medicine ,Diabetes mellitus ,medicine ,Pancreatitis ,Beta cell ,business - Abstract
Pancreatogenic diabetes mellitus, also termed type 3c diabetes (T3cD), or glucose intolerance develops in 25%-75% of adults with chronic pancreatitis (CP). The primary pathophysiologic defect in T3cD is insulin deficiency, thought to result largely from "bystander" injury to the islets from fibrotic changes in the exocrine pancreas and cytokine-induced beta cell dysfunction from intrapancreatic inflammation.
- Published
- 2021
13. Serum Biomarkers for Chronic Pancreatitis Pain Patterns
- Author
-
Kristen E Hall, Xianling Wang, Darwin L. Conwell, Andres Gelrud, Gregory A. Cote, Adam Slivka, Chris E. Forsmark, Kimberly Stello, David C. Whitcomb, Michele D. Lewis, Dhiraj Yadav, Jami L. Saloman, Samer Alkaade, Stuart Sherman, Peter A. Banks, Timothy B. Gardner, Randall E. Brand, and Gong Tang
- Subjects
medicine.medical_specialty ,Chemokine ,Endocrinology, Diabetes and Metabolism ,Population ,Pain ,Calcitonin gene-related peptide ,Disease cluster ,Gastroenterology ,Article ,Internal medicine ,Pancreatitis, Chronic ,medicine ,Humans ,education ,education.field_of_study ,Hepatology ,biology ,business.industry ,Interleukin-6 ,Tumor Necrosis Factor-alpha ,medicine.disease ,Nociception ,biology.protein ,Biomarker (medicine) ,Pancreatitis ,Tumor necrosis factor alpha ,business ,Biomarkers - Abstract
Objectives Chronic pancreatitis (CP) is associated with debilitating refractory pain. Distinct subtypes of CP pain have been previously characterized based on severity (none, mild-moderate, severe) and temporal (none, intermittent, constant) nature of pain, but no mechanism-based tools are available to guide pain management. This exploratory study was designed to determine if potential pain biomarkers could be detected in patient serum and whether they associate with specific pain patterns. Methods Cytokines, chemokines, and peptides associated with nociception and pain were measured in legacy serum samples from CP patients (N = 99) enrolled in the North American Pancreatitis Studies. The unsupervised hierarchical cluster analysis was applied to cluster CP patients based on their biomarker profile. Classification and regression tree was used to assess whether these biomarkers can predict pain outcomes. Results The hierarchical cluster analysis revealed a subset of patients with predominantly constant, mild-moderate pain exhibited elevated interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-2 (IL-2), tumor necrosis factor alpha (TNFα), and monocyte chemoattractant protein-1 (MCP1) whereas patients with higher interleukin-4 (IL-4), interleukin-8 (IL-8) and calcitonin gene related peptide (CGRP) were more likely to have severe pain. Interestingly, analyses of each individual biomarker revealed that patients with constant pain had reduced circulating TNFα and fractalkine. Patients with severe pain exhibited a significant reduction in TNFα as well as trends towards lower levels of IL-6 and substance P. Discussion The observations from this study indicate that unique pain experiences within the chronic pancreatitis population can be associated with distinct biochemical signatures. These data indicate that further hypothesis-driven analyses combining biochemical measurements and detailed pain phenotyping could be used to develop precision approaches for pain management in patients with chronic pancreatitis.
- Published
- 2021
14. Rectal Indomethacin Does Not Mitigate the Systemic Inflammatory Response Syndrome in Acute Pancreatitis: A Randomized Trial
- Author
-
Ioannis Pothoulakis, Phil A. Hart, Dhiraj Yadav, Jorge D. Machicado, David C. Whitcomb, Rawad Mounzer, Darwin L. Conwell, Pedram Paragomi, Peter Junwoo Lee, Georgios I. Papachristou, Alice Hinton, Phil J. Greer, and Enrique de-Madaria
- Subjects
Adult ,Male ,medicine.medical_specialty ,Randomization ,Population ,Indomethacin ,Placebo ,Gastroenterology ,Article ,law.invention ,Randomized controlled trial ,law ,Administration, Rectal ,Risk Factors ,Internal medicine ,Medicine ,Distribution (pharmacology) ,Humans ,education ,Adverse effect ,Pancreas ,Aged ,education.field_of_study ,business.industry ,Suppositories ,Anti-Inflammatory Agents, Non-Steroidal ,Middle Aged ,medicine.disease ,Systemic Inflammatory Response Syndrome ,Systemic inflammatory response syndrome ,Pancreatitis ,Disease Progression ,Acute pancreatitis ,Female ,business - Abstract
INTRODUCTION: Experimental data suggest that nonsteroidal antiinflammatory drugs may prevent disease severity and mortality in acute pancreatitis (AP). The aim of this study was to compare the efficacy of rectal indomethacin vs placebo in reducing the systemic inflammatory response syndrome (SIRS) score in a high-risk AP population for clinical progression. METHODS: We conducted a single-center, quadruple-blinded, randomized, placebo-controlled trial. Eligible criteria were subjects with AP and SIRS within 72 hours of presentation and those without organ failure. Subjects were allocated in a 1:1 ratio to indomethacin or placebo using simple randomization. Both interventions were administered rectally every 8 hours for 6 doses and compared using both intention-to-treat and per-protocol analyses. RESULTS: A total of 42 subjects (mean age 52 years, 55% men) were randomized to indomethacin (n = 18) or placebo (n = 24). There was no significant difference between the indomethacin and placebo groups in the change of SIRS score, proportion of subjects with SIRS, and distribution of SIRS scores at 24, 48, and 72 hours from randomization. There were no significant differences in the change of C-reactive protein levels at 48 hours or clinical outcomes between both treatment groups. Indomethacin was as safe as placebo, with 2 adverse events occurring in the placebo and none in the indomethacin arm. DISCUSSION: Rectal indomethacin can be safely administered over 48 hours; however, it is not superior to placebo in reducing the SIRS or clinical progression in a high-risk population with AP (ClinicalTrials.gov: NCT02692391).
- Published
- 2021
15. Pain Experience in Pancreatitis: Strong Association of Genetic Risk Loci for Anxiety and PTSD in Patients With Severe, Constant, and Constant-Severe Pain
- Author
-
Randall E. Brand, Samer Alkaade, Nalini M. Guda, Chris E. Forsmark, Phil J. Greer, Stuart Sherman, Ellyn K Dunbar, Michele D. Lewis, Georgios I. Papachristou, Dhiraj Yadav, David C. Whitcomb, C. Mel Wilcox, Adam Slivka, Joseph Romagnuolo, Stephen T. Amann, Thiruvengadam Muniraj, Darwin L. Conwell, Timothy B. Gardner, Jorge D. Machicado, Peter A. Banks, and Bimaljit S. Sandhu
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,medicine.disease ,Internal medicine ,Cohort ,Etiology ,Genetic predisposition ,Medicine ,Pancreatitis ,Anxiety ,FKBP5 ,medicine.symptom ,business ,Depression (differential diagnoses) ,Genetic association - Abstract
INTRODUCTION: Recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) are progressive inflammatory syndromes with variable features. Pain is the primary feature that contributes to low physical and mental quality of life with a third of patients reporting severe pain. Pain experience is worsened by depression. Here, we tested the hypothesis that genetic risk of the psychiatric conditions of anxiety and post-traumatic stress disorder (PTSD) is associated with pain in CP and RAP + CP subjects. METHODS: The study cohort included phenotyped and genotyped RAP and CP patients from the North American Pancreatitis Study II of European Ancestry. Candidate genetic association studies were based on the absence of pain vs pain that is constant, constant-severe, or severe. Twenty-eight candidate genetic loci for anxiety and PTSD risk were identified in the literature and were the focus of this study. RESULTS: We identified 24 significant pain-associated single nucleotide polymorphisms within 13 loci across the 3 pain patterns in CP and RAP + CP (P < 0.002). Thirteen anxiety or PTSD genes were within these pain loci indicating nonrandom associations (P < 4.885 × 10−23). CTNND2 was associated with all pain categories and all pancreatitis etiologies. Implicated systems include neuronal signaling (HTR2A, DRD3, NPY, and BDNF), hypothalamic-pituitary-adrenal axis (NR3C1 and FKBP5), and cell-cell interaction (CTNND2 and THBS2). DISCUSSION: A component of constant and severe pain in patients with RAP and CP is associated with genetic predisposition to anxiety and PTSD. Identification of patients at risk eligible for trials of targeted treatment as a component of a multidisciplinary pain management strategy should be formally evaluated.
- Published
- 2021
16. Barriers and Research Priorities for Implementing Precision Medicine
- Author
-
David C. Whitcomb
- Subjects
Hepatology ,Information Dissemination ,business.industry ,Research ,Endocrinology, Diabetes and Metabolism ,Pancreatic Diseases ,Precision medicine ,Data science ,Article ,Translational Research, Biomedical ,Endocrinology ,Internal Medicine ,Electronic Health Records ,Humans ,Medicine ,Precision Medicine ,Genetic Privacy ,business - Abstract
Effective management of complex pancreatic diseases demands precision medicine. While this new approach is technically feasible, many barriers to implementation impede realization of its promised benefits. Barriers exist in the acquisition and utilization of high quality, accurate, specific and quantitative information from both the clinical records and basic sciences. Barriers exist in integrating various domains of knowledge. Barriers exist in translating new insights from the bench to the bedside. Logistical barriers prevent seamless connection and interpretation of the necessary data elements. Barriers also exist with acceptance and application of precision medicine by major institutions and payers. Overcome these barriers will require high-level planning, clarity of vision into short and long term steps, and the commitment of innovative leaders, representing all stakeholders, to work together to reach a common goal.
- Published
- 2019
17. Lifetime Drinking History of Persons With Chronic Pancreatitis
- Author
-
Dhiraj Yadav, C. Mel Wilcox, Andres Gelrud, Christie Y. Jeon, David C. Whitcomb, Randall E. Brand, Adam Slivka, Nalini M. Guda, Gong Tang, Bimaljit S. Sandhu, Samer Alkaade, and Judah Abberbock
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Alcohol Drinking ,Original Manuscript ,Disease ,03 medical and health sciences ,Sex Factors ,0302 clinical medicine ,Interquartile range ,Pancreatitis, Chronic ,Surveys and Questionnaires ,Humans ,Medicine ,Longitudinal Studies ,Prospective Studies ,Pancreatitis, chronic ,Prospective cohort study ,Aged ,business.industry ,Smoking ,Age Factors ,General Medicine ,Middle Aged ,medicine.disease ,Alcoholism ,Pancreatitis ,030220 oncology & carcinogenesis ,Etiology ,Female ,030211 gastroenterology & hepatology ,Smoking status ,Lifetime Drinking History ,business - Abstract
Aims Cumulative consumption of alcohol and variations of alcohol intake by age are unknown in chronic pancreatitis (CP) patients in North America. This study summarizes the lifetime drinking history (LDH) by physician attribution of alcohol etiology, smoking status and sex in persons with CP. Methods We analyzed data on 193 CP participants who completed the LDH questionnaire in the North American Pancreatitis Continuation and Validation Study (NAPS2-CV). We collected data on frequency of drinking and drinks per drinking day for each drinking phase of their lives. We examined differences in total number of alcoholic drinks and weight of ethanol consumed by physician’s assessment of CP etiology, sex and smoking status. We also compared intensity of drinking in 20, 30 and 40s by timing of CP diagnosis. Results Persons diagnosed with alcoholic CP consumed median of 34,488 drinks (interquartile range 18,240–75,024) prior to diagnosis of CP, which occurred earlier than in persons with CP of other etiology (47 vs. 52 years). Cumulative drinking was greater in male vs. female patients. Male CP patients with a diagnosis of CP before the age of 45 drank more intensely in their 20s as compared to those with later onset of disease. Current smoking was prevalent (67%) among those diagnosed with alcoholic CP. Twenty-eight percent of patients without physician attribution of alcohol etiology reported drinking heavily in the past. Conclusions Lifetime cumulative consumption of alcohol and prevalence of current smoking are high in persons diagnosed with alcoholic pancreatitis. Intense drinking in early years is associated with earlier manifestation of the disease.
- Published
- 2019
18. Symptoms and Dietary Impact in Hypertriglyceridemia-Associated Pancreatitis: Development and Content Validity of Two New Measures
- Author
-
Karen Selk, Joshua A Strayer, Hayes Dansky, David C. Whitcomb, Cynthia J Girman, Robert J. Sanchez, Jason A. Randall, Erin E. Kershaw, Claire Burbridge, and Tara Symonds
- Subjects
Pharmacology ,medicine.medical_specialty ,Abdominal pain ,business.industry ,Health Policy ,Hypertriglyceridemia ,MEDLINE ,medicine.disease ,Clinical trial ,Internal medicine ,Content validity ,Medicine ,Acute pancreatitis ,Pancreatitis ,Pharmacology (medical) ,Original Research Article ,Thematic analysis ,medicine.symptom ,business - Abstract
Background Severe hypertriglyceridemia (sHTG) is a rare condition, complicated by episodes of acute pancreatitis (AP), which can cause pain and/or life-threatening multi-organ dysfunction. Currently, there are no disease-specific patient-reported outcome (PRO) measures evaluating symptoms or dietary impact for this condition. Objective The objective of this study was to explore patient-reported symptoms and impacts of sHTG and AP and develop new measures to capture the symptoms and dietary impacts of this condition using patient language. Methods In-depth, semi-structured concept elicitation interviews were conducted with 12 US-based participants to explore their experience and identify key symptoms and impact on dietary behavior, both during and between episodes of AP. Participants had a range of AP severity with a previous triglyceride reading > 1000 mg/dL, and at least one attack of AP within the last 12 months. Transcripts were coded using thematic analysis. Results Qualitative data analysis revealed the substantial burden of AP associated with sHTG. Participants reported experiencing symptoms, especially abdominal pain, both during and between attacks of AP, and discussed considerable diet changes to prevent or minimize future attacks. A conceptual model was refined, based on patient input, and reviewed by clinical experts to determine key concepts for inclusion within two PRO measures, one evaluating symptoms and another evaluating impact on dietary behavior. Items were drafted using patient-derived language. A 19-item symptoms measure [Hypertriglyceridemia and Acute Pancreatitis Symptom Scale (HAP-SS)] and a 6-item dietary impact measure (Hypertriglyceridemia and Acute Pancreatitis Dietary Behavior (HAP-DB) measure) were developed, both with a 24-h recall period. Conclusions The qualitative analysis confirmed the substantial burden of AP associated with sHTG. This research resulted in development of two disease-specific PRO measures for use during and between attacks of AP. These measures are being utilized in a clinical trial, which will confirm content, structure, and psychometric properties. Electronic supplementary material The online version of this article (10.1007/s41669-019-0155-y) contains supplementary material, which is available to authorized users.
- Published
- 2019
19. Acute Pancreatitis Task Force on Quality: Development of Quality Indicators for Acute Pancreatitis Management
- Author
-
Prashant Kedia, Stephen J. Pandol, Timothy B. Gardner, Rajesh Krishnamoorthi, Shyam Varadarajulu, Elaina Vivian, Paul R. Tarnasky, Richard Dickerman, Leslie Cler, Rathan Reddy, Mary Rachel Brooks, Samar Habash, Andrew S. Ross, Timothy Yen, Wahid Wassef, Hellen Oduor, Amrita Sethi, Santhi Swaroop Vege, Robert H. Hawes, Gregory A. Cote, Dhiraj Yadav, C. Mel Wilcox, Sheila Rastegari, Martin L. Freeman, Georgios I. Papachristou, Bechien U. Wu, David C. Whitcomb, Ashton Ellison, and Darwin L. Conwell
- Subjects
medicine.medical_specialty ,Consensus ,Delphi Technique ,media_common.quotation_subject ,Advisory Committees ,MEDLINE ,Delphi method ,Gallstones ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,Health care ,medicine ,Humans ,Pain Management ,Cholecystectomy ,Quality (business) ,Disease management (health) ,Intensive care medicine ,Quality Indicators, Health Care ,media_common ,Cholangiopancreatography, Endoscopic Retrograde ,Surgeons ,Analgesics ,Hepatology ,Nutritional Support ,Pancreatitis, Acute Necrotizing ,business.industry ,Gastroenterologists ,Gastroenterology ,Disease Management ,Reproducibility of Results ,medicine.disease ,Anti-Bacterial Agents ,Pancreatitis ,Hospitalists ,030220 oncology & carcinogenesis ,Drainage ,Fluid Therapy ,Acute pancreatitis ,030211 gastroenterology & hepatology ,business ,Risk assessment - Abstract
Detailed recommendations and guidelines for acute pancreatitis (AP) management currently exist. However, quality indicators (QIs) are required to measure performance in health care. The goal of the Acute Pancreatitis Task Force on Quality was to formally develop QIs for the management of patients with known or suspected AP using a modified version of the RAND/UCLA Appropriateness Methodology.A multidisciplinary expert panel composed of physicians (gastroenterologists, hospitalists, and surgeons) who are acknowledged leaders in their specialties and who represent geographic and practice setting diversity was convened. A literature review was conducted, and a list of proposed QIs was developed. In 3 rounds, panelists reviewed literature, modified QIs, and rated them on the basis of scientific evidence, bias, interpretability, validity, necessity, and proposed performance targets.Supporting literature and a list of 71 proposed QIs across 10 AP domains (Diagnosis, Etiology, Initial Assessment and Risk Stratification, etc.) were sent to the expert panel to review and independently rate in round 1 (95% of panelists participated). Based on a round 2 face-to-face discussion of QIs (75% participation), 41 QIs were classified as valid. During round 3 (90% participation), panelists rated the 41 valid QIs for necessity and proposed performance thresholds. The final classification determined that 40 QIs were both valid and necessary.Hospitals and providers managing patients with known or suspected AP should ensure that patients receive high-quality care and desired outcomes according to current evidence-based best practices. This physician-led initiative formally developed 40 QIs and performance threshold targets for AP management. Validated QIs provide a dependable quantitative framework for health systems to monitor the quality of care provided to patients with known or suspected AP.
- Published
- 2019
20. Protease-Sensitive Pancreatic Lipase Variants Are Associated With Early Onset Chronic Pancreatitis
- Author
-
András Szabó, Prachand Issarapu, Emmanuelle Masson, Peter Bugert, Denise Lasher, Sumit Paliwal, Claudia Ruffert, Shin Hamada, K. Radha Mani, Helmut Laumen, Jian-Min Chen, Atsushi Masamune, David A. Groneberg, Katharina Seltsam, Kiyoshi Kume, Xunjun Xiao, Maren Ewers, Eriko Nakano, M. Michael Barmada, Tooru Shimosegawa, Jonas Rosendahl, Giriraj R. Chandak, Thomas Müller, Mark E. Lowe, Miklós Sahin-Tóth, Heiko Witt, Seema Bhaskar, David C. Whitcomb, and Claude Férec
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Adolescent ,medicine.medical_treatment ,DNA Mutational Analysis ,medicine.disease_cause ,Article ,Pathogenesis ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Pancreatitis, Chronic ,Internal medicine ,medicine ,Humans ,Pancreatic lipase ,Genetic Predisposition to Disease ,Child ,Gene ,Early onset ,Mutation ,Protease ,Virulence ,Hepatology ,biology ,business.industry ,Infant, Newborn ,Gastroenterology ,Infant ,DNA ,Lipase ,medicine.disease ,Trypsin ,Endocrinology ,Child, Preschool ,030220 oncology & carcinogenesis ,biology.protein ,Pancreatitis ,Female ,030211 gastroenterology & hepatology ,business ,Biomarkers ,Follow-Up Studies ,Peptide Hydrolases ,medicine.drug - Abstract
OBJECTIVES. Premature activation of the digestive protease trypsin within the pancreatic parenchyma is a critical factor in the pathogenesis of pancreatitis. Alterations in genes that affect intra-pancreatic trypsin activity are associated with chronic pancreatitis (CP). Recently, carboxyl ester lipase (CEL) emerged as a trypsin-independent risk gene. Here, we evaluated PNLIP encoding pancreatic lipase as a potential novel susceptibility gene for CP. METHODS. We analyzed all 13 PNLIP exons in 429 German non-alcoholic CP patients and in 600 German control subjects, in 632 patients and 957 controls from France, and in 223 patients and 1070 controls from Japan by DNA sequencing. Additionally, we analyzed selected exons in further 545 CP patients and 1849 controls originating from Germany, USA and India. We assessed the cellular secretion, lipase activity and proteolytic stability of recombinant PNLIP variants. RESULTS. In the German discovery cohort, 8/429 (1.9%) patients and 2/600 (0.3%) controls carried a PNLIP missense variant (P=0.02, OR=5.7, 95% CI=1.1–38.9). Variants detected in patients were prone to proteolytic degradation by trypsin and chymotrypsin. In the French replication cohort, protease-sensitive variants were also enriched in patients with early-onset CP (5/632 [0.8%]) versus controls (1/957 [0.1%]) (P=0.04, OR=7.6, 95% CI=0.9–172.9). In contrast, we detected no protease-sensitive variants in the non-European populations. In the combined European data, protease-sensitive variants were found in 13/1163 cases (1.1%) and in 3/3000 controls (0.1%) (OR=11.3, 95% CI=3.0–49.9, P
- Published
- 2019
21. Lifetime smoking history and cohort-based smoking prevalence in chronic pancreatitis
- Author
-
Nalini M. Guda, David C. Whitcomb, Christie Y. Jeon, Robert G. Feldman, Samer Alkaade, Randall E. Brand, Bimaljit S. Sandhu, Andres Gelrud, Dhiraj Yadav, C. Mel Wilcox, Andrew D. Althouse, Adam Slivka, and Vikesh K. Singh
- Subjects
medicine.medical_specialty ,Epidemiology ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Clinical Sciences ,Smoking prevalence ,Smoking history ,Article ,03 medical and health sciences ,Substance Misuse ,0302 clinical medicine ,Clinical Research ,Internal medicine ,Tobacco ,medicine ,In patient ,Cancer ,Pediatric ,Chronic Pancreatitis ,Hepatology ,Tobacco Smoke and Health ,Gastroenterology & Hepatology ,business.industry ,Prevention ,Smoking ,Pain Research ,Gastroenterology ,Cohort ,medicine.disease ,030220 oncology & carcinogenesis ,Respiratory ,Smoking cessation ,Pancreatitis ,030211 gastroenterology & hepatology ,Smoking status ,Chronic Pain ,business ,Digestive Diseases - Abstract
BACKGROUND/OBJECTIVE: Smoking prevalence in patients with chronic pancreatitis [CP] is high. We aimed to understand lifetime history of smoking and cohort trends in CP patients to inform effective strategies for smoking cessation. METHOD: Data on 317 CP patients from the North American Pancreatitis Study 2 [NAPS2] Continuation and Validation Study and the NAPS2 Ancillary Study were analyzed. Smoking history was assessed for each phase of life from the onset of smoking to study enrollment. Data on second-hand smoke and drinking history were also collected. We compared demographic factors, drinking history, pain level and pancreas morphology by smoking status at age 25 (non-smoking
- Published
- 2021
22. A Novel 5-Cytokine Panel Outperforms Conventional Predictive Markers of Persistent Organ Failure in Acute Pancreatitis
- Author
-
Christopher J. Langmead, Phil A. Hart, Georgios I. Papachristou, Kim Stello, Peter Lee, Phil J. Greer, David C. Whitcomb, and Pedram Paragomi
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Multiple Organ Failure ,Information Theory ,Article ,Machine Learning ,03 medical and health sciences ,0302 clinical medicine ,Text mining ,Internal medicine ,medicine ,Humans ,Disease process ,Pancreas ,Aged ,business.industry ,Angiopoietin 2 ,Gastroenterology ,Area under the curve ,Middle Aged ,medicine.disease ,Prognosis ,Cytokine ,Pancreatitis ,030220 oncology & carcinogenesis ,Cohort ,Acute pancreatitis ,Cytokines ,030211 gastroenterology & hepatology ,Resistin ,Female ,business ,Biomarkers - Abstract
Introduction Existing laboratory markers and clinical scoring systems have shown suboptimal accuracies for early prediction of persistent organ failure (POF) in acute pancreatitis (AP). We used information theory and machine learning to select the best-performing panel of circulating cytokines for predicting POF early in the disease course and performed verification of the cytokine panel's prognostic accuracy in an independent AP cohort. Methods The derivation cohort included 60 subjects with AP with early serum samples collected between 2007 and 2010. Twenty-five cytokines associated with an acute inflammatory response were ranked by computing the mutual information between their levels and the outcome of POF; 5 high-ranking cytokines were selected. These cytokines were subsequently measured in early serum samples of an independent prospective verification cohort of 133 patients (2012-2016), and the results were trained in a Random Forest classifier. Cross-validated performance metrics were compared with the predictive accuracies of conventional laboratory tests and clinical scores. Results Angiopoietin 2, hepatocyte growth factor, interleukin 8, resistin, and soluble tumor necrosis factor receptor 1A were the highest-ranking cytokines in the derivation cohort; each reflects a pathologic process relevant to POF. A Random Forest classifier trained the cytokine panel in the verification cohort and achieved a 10-fold cross-validated accuracy of 0.89 (area under the curve 0.91, positive predictive value 0.89, and negative predictive value 0.90), which outperformed individual cytokines, laboratory tests, and clinical scores (all P ≤ 0.006). Discussion We developed a 5-cytokine panel, which accurately predicts POF early in the disease process and significantly outperforms the prognostic accuracy of existing laboratory tests and clinical scores.
- Published
- 2021
23. Dynamic changes in the pancreatitis activity scoring system during hospital course in a multicenter, prospective cohort
- Author
-
Gong Tang, Gregory A. Cote, Ayesha Kamal, Anna E. Phillips, Phil A. Hart, David C. Whitcomb, James Buxbaum, Bechien U. Wu, Phil J. Greer, Vikesh K. Singh, Ioannis Pothoulakis, Jeffrey J. Easler, Venkata S. Akshintala, Tyler Stevens, Pedram Paragomi, Georgios I. Papachristou, Amir Gougol, Darwin L. Conwell, Marie Tuft, Peter Lee, Shyam Thakkar, Haq Nawaz, and Jorge D. Machicado
- Subjects
medicine.medical_specialty ,Scoring system ,Severity of Illness Index ,Article ,03 medical and health sciences ,0302 clinical medicine ,Disease severity ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Generalized estimating equation ,Morphine Derivatives ,Hepatology ,business.industry ,Gastroenterology ,medicine.disease ,Hospitalization ,Pancreatitis ,030220 oncology & carcinogenesis ,Cohort ,Acute Disease ,Acute pancreatitis ,030211 gastroenterology & hepatology ,business ,Hospital stay - Abstract
BACKGROUND AND AIM: The primary aim was to validate the Pancreatitis Activity Scoring System (PASS) in a multicenter prospectively ascertained acute pancreatitis (AP) cohort. Second, we investigated the association of early PASS trajectories with disease severity and length of hospital stay (LOS). METHODS: Data were prospectively collected through the APPRENTICE consortium (2015-2018). AP severity was categorized based on revised Atlanta classification. Delta PASS (ΔPASS) was calculated by subtracting activity score from baseline value. PASS trajectories were compared between severity subsets. Subsequently, the cohort was subdivided into three LOS subgroups as short (S-LOS): 2-3 days; intermediate (I-LOS): 3-7 days; and long (L-LOS): ≥7 days. The generalized estimating equations model was implemented to compare PASS trajectories. RESULTS: There were 434 subjects analyzed including 322 (74%) mild, 86 (20%) moderately severe, and 26 (6%) severe AP. Severe AP subjects had the highest activity levels and the slowest rate of decline in activity (P = 0.039). Focusing on mild AP, L-LOS subjects (34%) had 28 points per day slower decline; whereas, S-LOS group (13%) showed 34 points per day sharper decrease compared with I-LOS (53%; P
- Published
- 2020
24. Natural course of pain in chronic pancreatitis is independent of disease duration
- Author
-
Randall E. Brand, David C. Whitcomb, Kenneth K. Lee, Andrew D. Althouse, Allison Kanakis, Georgios I. Papachristou, Jennifer Chennat, Kishore Vipperla, Dhiraj Yadav, Amer H. Zureikat, Anna E. Phillips, and Adam Slivka
- Subjects
Adult ,Male ,medicine.medical_specialty ,Abdominal pain ,Time Factors ,Endocrinology, Diabetes and Metabolism ,Disease duration ,Severity of Illness Index ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Pancreatitis, Chronic ,medicine ,Severe pain ,Humans ,Longitudinal Studies ,Aged ,Pain Measurement ,Retrospective Studies ,Natural course ,Hepatology ,business.industry ,Medical record ,Gastroenterology ,Clinical course ,Middle Aged ,medicine.disease ,Abdominal Pain ,Logistic Models ,030220 oncology & carcinogenesis ,Cohort ,Disease Progression ,Pancreatitis ,030211 gastroenterology & hepatology ,Female ,medicine.symptom ,business - Abstract
Pain burn-out during the course of chronic pancreatitis (CP), proposed in the 1980s, remains controversial, and has clinical implications. We aimed to describe the natural course of pain in a well-characterized cohort.We constructed the clinical course of 279 C P patients enrolled from 2000 to 2014 in the North American Pancreatitis Studies from UPMC by retrospectively reviewing their medical records (median observation period, 12.4 years). We assessed abdominal pain at different time points, characterized pain pattern (Type A [short-lived pain episodes] or B [persistent pain and/or clusters of recurrent severe pain]) and recorded information on relevant covariates.Pain at any time, at the end of follow-up, Type A pain pattern or B pain pattern was reported by 89.6%, 46.6%, 34% and 66% patients, respectively. In multivariable analyses, disease duration (time from first diagnosis of pancreatitis to end of observation) did not associate with pain - at last clinical contact (OR, 1.0, 95% CI 0.96-1.03), at NAPS2 enrollment (OR 1.02, 95% CI 0.96-1.07) or Type B pain pattern (OR 1.01, 95% CI 0.97-1.04). Patients needing endoscopic or surgical therapy (97.8 vs. 75.2%, p 0.001) and those with alcohol etiology (94.7 vs. 84.9%, p = 0.007) had a higher prevalence of pain. In multivariable analyses, invasive therapy associated with Type B pain and pain at last clinical contact.Only a subset of CP patients achieve durable pain relief. There is urgent need to develop new strategies to evaluate and manage pain, and to identify predictors of response to pain therapies for CP.
- Published
- 2020
25. The Histopathology of SPINK1-associated Chronic Pancreatitis
- Author
-
Marina N. Nikiforova, Gregory J. Beilman, Melena D. Bellin, Dhiraj Yadav, Martin Wijkstrom, Srinath Chinnakotla, Jennifer Chennat, Abigail I. Wald, David C. Whitcomb, Sarah Jane Schwarzenberg, Terrell E. Jones, Varvara A. Kirchner, Aatur D. Singhi, Amer H. Zureikat, Martin L. Freeman, Timothy L. Pruett, Abhinav Humar, and Adam Slivka
- Subjects
Adult ,medicine.medical_specialty ,Abdominal pain ,Adolescent ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Pancreatic Intraepithelial Neoplasia ,Disease ,Gastroenterology ,Article ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Atrophy ,Fibrosis ,Internal medicine ,Pancreatitis, Chronic ,medicine ,Humans ,Genetic Predisposition to Disease ,Child ,Hepatology ,business.industry ,Middle Aged ,medicine.disease ,Autotransplantation ,Abdominal Pain ,Trypsin Inhibitor, Kazal Pancreatic ,030220 oncology & carcinogenesis ,Child, Preschool ,Mutation ,Pancreatitis ,030211 gastroenterology & hepatology ,Histopathology ,medicine.symptom ,business - Abstract
Background The identification of genetic risk factors for chronic pancreatitis, such as PRSS1, CFTR and SPINK1, provides the opportunity to define key pathologic hallmarks and etiologic-specific changes. For example, pancreata from PRSS1 and CFTR patients exhibit progressive lipomatous atrophy without significant fibrosis. Considering the pathology of SPINK1-associated pancreatitis is ill-defined, we examined the pancreata of SPINK1 patients with chronic pancreatitis. Methods Histologic sections after total pancreatectomy with islet autotransplantation and associated clinicopathologic data were collected from 28 patients with SPINK1 germline alterations. Clinical findings, germline data, anatomic anomalies and pathologic findings were descriptively evaluated. Results Patients ranged in age from 5 to 48 years (median, 21.6 years) with abdominal pain between 2 and 25 years (median, 5.8 years). Most patients were SPINK1 heterozygous and 14 (50%) had co-occurring CFTR (n = 12) and CTRC (n = 2) mutations. Other pancreatitis risk factors included anatomic anomalies (n = 9) and tobacco use (n = 1). Overall, 24 (86%) patients had additional pancreatitis-associated germline alterations, SPINK1 homozygosity, anatomic anomalies or environmental factors. Examination of pancreata revealed a sequential pattern of exocrine parenchymal loss and replacement by prominent fibrosis, dependent on the duration of abdominal pain. No malignancies were identified, but low-grade pancreatic intraepithelial neoplasia was present for 2 cases. Conclusions Within this descriptive study, SPINK1-associated pancreatitis is characterized by parenchymal fibrosis and suggests divergent pathophysiologic mechanisms from PRSS1 and CFTR-associated pancreatitis. Moreover, SPINK1 patients frequently had additional etiologic factors that did not impact the development of pancreatic fibrosis and may implicate SPINK1 as a disease modifier gene.
- Published
- 2020
26. International consensus guidelines on interventional endoscopy in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club
- Author
-
Shuiji Isaji, David C. Whitcomb, Hiroyuki Isayama, Phillipe Lévy, Thomas M. Gress, Pramod Kumar Garg, John P. Neoptolemos, Asbjørn Mohr Drewes, C. Mel Wilcox, Masayuki Kitano, Carlos Fernandez-del Castillo, Atsushi Kanno, Kei Takase, Andrea Sheel, Tooru Shimosegawa, Michael J. Levy, Takao Itoi, Marja A. Boermeester, Atsushi Irisawa, Ichiro Yasuda, Surgery, AII - Inflammatory diseases, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism
- Subjects
medicine.medical_specialty ,Consensus ,Pancreatic pseudocyst ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Pain ,Guidelines as Topic ,03 medical and health sciences ,ERCP ,0302 clinical medicine ,Pancreatectomy ,Lithotripsy ,Pancreatitis, Chronic ,Hemosuccus pancreaticus ,medicine ,Humans ,Pain Management ,EUS ,Cholangiopancreatography, Endoscopic Retrograde ,Pancreatic duct ,Hepatology ,medicine.diagnostic_test ,business.industry ,General surgery ,Pancreatic Ducts ,Gastroenterology ,Calcinosis ,Endoscopy ,Guideline ,Cholestasis, Extrahepatic ,medicine.disease ,medicine.anatomical_structure ,Pancreatic fistula ,030220 oncology & carcinogenesis ,Pancreatitis ,030211 gastroenterology & hepatology ,Surgery ,business ,ESWL - Abstract
Background/objectives This paper is part of the international consensus guidelines on chronic pancreatitis, presenting for interventional endoscopy. Methods An international working group with experts on interventional endoscopy evaluated 26 statements generated from evidence on 9 clinically relevant questions. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to evaluate the level of evidence. To determine the level of agreement, a nine-point Likert scale was used for voting on the statements. Results Strong consensus was obtained for 15 statements relating to nine questions including the recommendation that endoscopic intervention should be offered to patients with persistent severe pain but not to those without pain. Endoscopic decompression of the pancreatic duct could be used for immediate pain relief, and then offered surgery if this fails or needs repeated endoscopy. Endoscopic drainage is preferred for portal-splenic vein thrombosis and pancreatic fistula. A plastic stent should be placed and replaced 2–3 months later after insertion. Endoscopic extraction is indicated for stone fragments remaining after ESWL. Interventional treatment should be performed for symptomatic/complicated pancreatic pseudocysts. Endoscopic treatment is recommended for bile duct obstruction and afterwards surgery if this fails or needs repeated endoscopy. Surgery may be offered if there is significant calcification and/or mass of the pancreatic head. Percutaneous endovascular treatment is preferred for hemosuccus pancreaticus. Surgical treatment is recommended for duodenal stenosis due to chronic pancreatitis. Conclusions This international expert consensus guideline provides evidenced-based statements concerning indications and key aspects for interventional endoscopy in the management of patients with chronic pancreatitis.
- Published
- 2020
27. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club
- Author
-
Carlos Fernandez-del Castillo, Julia Mayerle, William Greenhalf, Markus M. Lerch, Andrea Sheel, Philippe Lévy, Patrick Maisonneuve, Chris E. Forsmark, Maiken Thyregod Jørgensen, Vinciane Rebours, Jörg Kleeff, John P. Neoptolemos, Shuiji Isaji, Kyoichi Takaori, Christopher Halloran, Steve Pandol, Dhiraj Yadav, Pramod Kumar Garg, Thomas M. Gress, Péter Hegyi, Randall E. Brand, Suresh T. Chari, Marc G. Besselink, David C. Whitcomb, C. Mel Wilcox, Tooru Shimosegawa, Surgery, CCA - Cancer Treatment and Quality of Life, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism
- Subjects
Male ,Endocrinology, Diabetes and Metabolism ,0302 clinical medicine ,Japan ,Trypsin ,EUS ,Aged, 80 and over ,Hereditary pancreatitis ,Evidence-Based Medicine ,Age Factors ,Gastroenterology ,Middle Aged ,medicine.anatomical_structure ,Trypsin Inhibitor, Kazal Pancreatic ,Population Surveillance ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,Club ,Pancreas ,Adult ,CT scan ,medicine.medical_specialty ,Consensus ,Guidelines as Topic ,03 medical and health sciences ,Pancreatitis, Chronic ,Pancreatic cancer ,Internal medicine ,medicine ,Genetics ,Humans ,Genetic Predisposition to Disease ,In patient ,Life Style ,Aged ,Markers ,Hepatology ,business.industry ,Evidence-based medicine ,medicine.disease ,United States ,Pancreatic Neoplasms ,Treatment ,Increased risk ,Risk factors ,Pancreatitis ,Surgery ,business - Abstract
Background Patients with chronic pancreatitis (CP) have an increased risk of pancreatic cancer. We present the international consensus guidelines for surveillance of pancreatic cancer in CP. Methods The international group evaluated 10 statements generated from evidence on 5 questions relating to pancreatic cancer in CP. The GRADE approach was used to evaluate the level of evidence available per statement. The working group voted on each statement for strength of agreement, using a nine-point Likert scale in order to calculate Cronbach’s alpha reliability coefficient. Results In the following domains there was strong consensus: (1) the risk of pancreatic cancer in affected individuals with hereditary pancreatitis due to inherited PRSS1 mutations is high enough to justify surveillance; (2) the risk of pancreatic cancer in patients with CP associated with SPINK1 p. N34S is not high enough to justify surveillance; (3) surveillance should be undertaken in pancreatic specialist centers; (4) surveillance should only be introduced after the age of 40 years and stopped when the patient would no longer be suitable for surgical intervention. All patients with CP should be advised to lead a healthy lifestyle aimed at avoiding risk factors for progression of CP and pancreatic cancer. There was only moderate or weak agreement on the best methods of screening and surveillance in other types of environmental, familial and genetic forms of CP. Conclusions Patients with inherited PRSS1 mutations should undergo surveillance for pancreatic cancer, but the best methods for cancer detection need further investigation.
- Published
- 2020
28. Assessment of Weight Loss and Gastrointestinal Symptoms Suggestive of Exocrine Pancreatic Dysfunction After Acute Pancreatitis
- Author
-
Nicole L Komara, Pedram Paragomi, Kimberly Stello, Ioannis Pothoulakis, Ali Lahooti, Diala Harb, Filippos Koutroumpakis, Anna E. Phillips, Kohtaro Ooka, Melanie Mays, Phil J. Greer, Georgios I. Papachristou, and David C. Whitcomb
- Subjects
Adult ,Male ,medicine.medical_specialty ,Logistic regression ,Gastroenterology ,Severity of Illness Index ,Article ,Body Mass Index ,03 medical and health sciences ,0302 clinical medicine ,Weight loss ,Risk Factors ,Internal medicine ,Diabetes mellitus ,Weight Loss ,medicine ,Diabetes Mellitus ,Humans ,Prospective Studies ,Pancreas ,Generalized estimating equation ,Aged ,business.industry ,Incidence (epidemiology) ,Middle Aged ,medicine.disease ,Prognosis ,Natural history ,Pancreatitis ,030220 oncology & carcinogenesis ,Acute pancreatitis ,030211 gastroenterology & hepatology ,Exocrine Pancreatic Insufficiency ,Female ,medicine.symptom ,business ,Body mass index ,Follow-Up Studies - Abstract
INTRODUCTION: Studies evaluating the natural history of exocrine pancreatic dysfunction (EPD) after acute pancreatitis (AP) are sparse. This study aims to assess incidence and predictors of weight loss and gastrointestinal (GI) symptoms suggestive of EPD 12 months after an AP episode. METHODS: Patients enrolled in the Pancreatitis-associated Risk of Organ Failure Study at the time of an AP episode were included. Weight and GI symptom data were prospectively collected by self-report at enrollment and at 3- and 12-month (windows 2–7 and 8–20) telephone follow-ups. Multivariable logistic regression was used to assess factors associated with ≥10% total body weight loss (EPD surrogate) at 12 months. A generalized estimating equation was used to measure each factor's population effect (in pounds) over 12 months after AP. RESULTS: Follow-up at 12 months in 186 patients (median age = 54 years, 46% men, 45% biliary, 65% first AP attack) revealed weight loss ≥10% from baseline, occurring in 44 patients (24%). Risk of weight loss increased with higher baseline body mass index, previous diagnosis of diabetes mellitus, and worsening AP severity (all P < 0.010). GI symptoms were reported in 13/31 (42%) patients at 12 months. AP severity was independently associated with ≥10% weight loss at 12 months. Over 12 months, men lost more weight than women (average 9.5 lbs); patients with severe AP lost, on average, 14 lbs. DISCUSSION: Weight loss after AP occurs in one-quarter of patients and is associated with AP severity. EPD incidence after AP is likely underappreciated. Further work is needed to assess EPD and potential for pancreatic enzyme supplementation.
- Published
- 2020
29. Constant-severe pain in chronic pancreatitis is associated with genetic loci for major depression in the NAPS2 cohort
- Author
-
Vikesh K. Singh, Stuart Sherman, Charles M. Wilcox, Timothy B. Gardner, Georgios I. Papachristou, Chris E. Forsmark, Gregory A. Cote, Andres Gelrud, David C. Whitcomb, Samer Alkaade, Phil J. Greer, Randall E. Brand, Nalini M. Guda, Jorge D. Machicado, Stephen T. Amann, Bimaljit S. Sandhu, Nadine M. Melhem, Thiruvengadam Muniraj, Michele D. Lewis, Dhiraj Yadav, Jessica LaRusch, Ellyn K Dunbar, and Joseph Romagnuolo
- Subjects
Adult ,Male ,medicine.medical_specialty ,Genotype ,Pain ,Severity of Illness Index ,Article ,law.invention ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Quality of life ,law ,Internal medicine ,Pancreatitis, Chronic ,medicine ,Genetic predisposition ,Humans ,Depression (differential diagnoses) ,Aged ,Retrospective Studies ,Depressive Disorder, Major ,business.industry ,Gastroenterology ,Chronic pain ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Antidepressive Agents ,Genetic Loci ,030220 oncology & carcinogenesis ,Cohort ,Quality of Life ,Pancreatitis ,030211 gastroenterology & hepatology ,Female ,business ,Genome-Wide Association Study - Abstract
Pain is the most debilitating symptom of recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) and often requires chronic opioids or total pancreatectomy with islet autotransplantation to manage. Pain is a complex experience that can be exacerbated by depression and vice versa. Our aim was to test the hypothesis that depression-associated genes are associated with a constant-severe pain experience in RAP/CP patients. A retrospective study was done using North American Pancreatitis Study II (NAPS2) genotyped RAP and CP patients with completed case report forms (n = 1,357). Subjects were divided based on pattern of pain and pain severity as constant-severe pain (n = 787) versus not constant-severe pain (n = 570) to conduct a nested genome-wide association study. The association between reported antidepressant medication use and depression gene loci was tested. Constant-severe pain was reported in 58% (n = 787) of pancreatitis patients. No differences in sex or alcohol consumption were found based on pain severity. Antidepressant use was reported in 28% (n = 223), and they had lower SF-12 mental quality of life (MCS, p
- Published
- 2020
30. ACG Clinical Guideline: Chronic Pancreatitis
- Author
-
Timothy B. Gardner, Chris E. Forsmark, David C. Whitcomb, Jason R. Taylor, Douglas G. Adler, and Bryan G. Sauer
- Subjects
medicine.medical_specialty ,Abdominal pain ,medicine.medical_treatment ,Clinical Decision-Making ,Disease ,03 medical and health sciences ,0302 clinical medicine ,Pancreatectomy ,Pancreatitis, Chronic ,medicine ,Humans ,Intensive care medicine ,Exocrine pancreatic insufficiency ,Hepatology ,business.industry ,Patient Selection ,Gastroenterology ,Guideline ,medicine.disease ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Acute pancreatitis ,Pancreatitis ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,Pancreas - Abstract
Chronic pancreatitis (CP) is historically defined as an irreversible inflammatory condition of the pancreas leading to varying degrees of exocrine and endocrine dysfunction. Recently however, the paradigm for the diagnosis has changed in that it breaks with the traditional clinicopathologic-based definition of disease, focusing instead on diagnosing the underlying pathologic process early in the disease course and managing the syndrome more holistically to change the natural course of disease and minimize adverse disease effects. Currently, the most accepted mechanistically derived definition of CP is a pathologic fibroinflammatory syndrome of the pancreas in individuals with genetic, environmental, and/or other risk factors who develop persistent pathologic responses to parenchymal injury or stress. The most common symptom of CP is abdominal pain, with other symptoms such as exocrine pancreatic insufficiency and diabetes developing at highly variable rates. CP is most commonly caused by toxins such as alcohol or tobacco use, genetic polymorphisms, and recurrent attacks of acute pancreatitis, although no history of acute pancreatitis is seen in many patients. Diagnosis is made usually on cross-sectional imaging, with modalities such as endoscopic ultrasonography and pancreatic function tests playing a secondary role. Total pancreatectomy represents the only known cure for CP, although difficulty in patient selection and the complications inherent to this intervention make it usually an unattractive option. This guideline will provide an evidence-based practical approach to the diagnosis and management of CP for the general gastroenterologist.
- Published
- 2020
31. Clinical Characteristics of Inflammatory Bowel Disease Patients Requiring Long-Term Parenteral Support in the Present Era of Highly Effective Biologic Therapy
- Author
-
David C. Whitcomb, Juliette Bender-Heine, Elisabeth Kramer, David J. Levinthal, Claudia Ramos Rivers, David G. Binion, Michael Kurin, Stephen J. O'Keefe, Jana G. Hashash, Alyce Anderson, Michael A. Dunn, Filippos Koutroumpakis, Gina M. Kozak, Ioannis E. Koutroubakis, and patricia centa
- Subjects
Short Bowel Syndrome ,medicine.medical_specialty ,030309 nutrition & dietetics ,Medicine (miscellaneous) ,Disease ,Inflammatory bowel disease ,Teduglutide ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Interquartile range ,Internal medicine ,medicine ,Humans ,Prospective Studies ,0303 health sciences ,Crohn's disease ,Nutrition and Dietetics ,business.industry ,Short bowel syndrome ,medicine.disease ,Inflammatory Bowel Diseases ,digestive system diseases ,Biological Therapy ,Parenteral nutrition ,chemistry ,030211 gastroenterology & hepatology ,Observational study ,business ,Parenteral Nutrition, Home - Abstract
Background Despite advances in the medical management of inflammatory bowel disease (IBD), a subset of patients may require extensive surgery, leading to short-bowel syndrome/intestinal failure requiring long-term home parenteral nutrition (PN) or customized intravenous fluid (IVF) support. Our aim was to further define the characteristics of IBD patients requiring home PN/IVF. Methods This is an observational study from a prospective IBD research registry. Patients receiving long-term home PN/IVF support during 2009-2015 were identified and compared with remaining IBD patients. Demographics, surgical history, smoking, narcotic use, IBD treatment, healthcare charges, and presence of biomarkers were reviewed. The IBD-PN group was stratified into 3 groups based on median healthcare charges. Results Of 2359 IBD patients, there were 25 (1%, 24 with Crohn's disease) who required home PN/IVF, and 250 randomly selected IBD patients matched for disease type formed the control population. Median duration of PN use was 27 months (interquartile range, 11-66). PN use was significantly associated with smoking, narcotic use, IBD-related operations, and lower quality-of-life scores. Among IBD-PN patients, 7 of 25 (28%, 3 after use of teduglutide) were able to successfully discontinue this modality. Median healthcare charges in the IBD-PN group were $51,456 annually. Median charges in the controls were $3427. Period prevalence mortality was 11.5% in IBD-PN and 3.8% in controls. Conclusions IBD patients requiring long-term home PN/IVF support are a small minority in the present era of immunomodulator/biologic therapy. These refractory patients have a 15-fold increase in annual median healthcare charges compared with control IBD patients.
- Published
- 2020
32. Bone health assessment in clinical practice is infrequenty performed in patients with chronic pancreatitis
- Author
-
David C. Whitcomb, Georgios I. Papachristou, Adam Slivka, Randall E. Brand, Kishore Vipperla, Allison Kanakis, and Dhiraj Yadav
- Subjects
Male ,medicine.medical_specialty ,FRAX ,Endocrinology, Diabetes and Metabolism ,Health Status ,Osteoporosis ,Population ,Bone health ,Risk Assessment ,Article ,03 medical and health sciences ,0302 clinical medicine ,Absorptiometry, Photon ,Predictive Value of Tests ,Internal medicine ,Pancreatitis, Chronic ,medicine ,Prevalence ,Humans ,education ,Aged ,Retrospective Studies ,Aged, 80 and over ,Hip fracture ,education.field_of_study ,Hepatology ,business.industry ,Medical record ,Gastroenterology ,Age Factors ,Middle Aged ,medicine.disease ,Confidence interval ,030220 oncology & carcinogenesis ,Pancreatitis ,030211 gastroenterology & hepatology ,Female ,Bone Diseases ,business ,Osteoporotic Fractures - Abstract
BACKGROUND: Chronic pancreatitis (CP) patients have a high prevalence of osteoporotic fractures. In addition to prevalence of osteoporotic fractures, we evaluated how often bone health is assessed by dual-energy x-ray absorptiometry (DXA) in clinical practice, and the performance of Fracture Risk Assessment Tool (FRAX(®)) in predicting fracture risk in CP patients. METHODS: Medical records of CP patients age ≥40 years prospectively enrolled in the North American Pancreatitis Study 2 (NAPS2) from the University of Pittsburgh Medical Center from 2000-2014 were retrospectively reviewed to gather additional relevant data before, at, and after enrollment until 12/2016. We determined if patients underwent DXA, compared their observed prevalence of fractures with published data from two large US studies based on administrative data, and their predicted fracture risk with US population based on FRAX(®). RESULTS: Only 21% (49/239) patients were evaluated by DXA during their care. The observed cumulative prevalence of fragility fractures in NAPS2 CP patients (9.2%, 95% confidence interval 5.9-13.6) was significantly greater than in controls (1.46% and 2.16%, p≤0.001 for each comparison) and CP patients (4.66%, and 5.13%, p0.05) and for hip fracture of ≥3% (19.6% vs. 18.9%, p>0.05) in NAPS2 CP patients did not differ from the US population. CONCLUSIONS: Despite their high risk of fragility fractures, bone health is infrequently assessed in CP patients. FRAX(®) may not adequately predict fracture risk in CP patients.
- Published
- 2020
33. Introduction and Validation of a Novel Acute Pancreatitis Digital Tool Interrogating Large Pooled Data From 2 Prospectively Ascertained Cohorts
- Author
-
Shyam Thakkar, Cameron R. Breze, Daniel M. Spagnolo, Rupjyoti Talukdar, Haq Nawaz, Vikesh K. Singh, Konstantinos Triantafyllou, Ioannis Pothoulakis, Amir Gougol, Bechien U. Wu, David C. Whitcomb, Gregory A. Cote, Mahesh Kumar Goenka, Sorin T. Barbu, Tyler Stevens, Aiste Gulla, Carlos Ocampo, Pedram Paragomi, Jose A Gonzalez, Mario Pelaez-Luna, Georgios I. Papachristou, Enrique de-Madaria, Miguel Ferreira, Livia Archibugi, Rakesh Kochhar, Silvia C. Gutierrez, Mark Haupt, Narcis O. Zarnescu, and Jeffrey J. Easler
- Subjects
Male ,medicine.medical_specialty ,Post hoc ,acute pancreatitis ,Endocrinology, Diabetes and Metabolism ,precision medicine ,MEDLINE ,Pilot Projects ,outcomes ,Clinical decision support system ,Risk Assessment ,Severity of Illness Index ,Decision Support Techniques ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Predictive Value of Tests ,Risk Factors ,Internal Medicine ,medicine ,Humans ,Pooled data ,organ failure ,Prospective Studies ,pancreas ,Hepatology ,Patient registry ,business.industry ,Reproducibility of Results ,Middle Aged ,medicine.disease ,Prognosis ,Predictive value ,Pancreatitis ,030220 oncology & carcinogenesis ,Emergency medicine ,Acute pancreatitis ,030211 gastroenterology & hepatology ,Female ,business ,Sudden onset - Abstract
Objectives Acute pancreatitis (AP) is a sudden onset, rapidly evolving inflammatory response with systemic inflammation and multiorgan failure (MOF) in a subset of patients. New highly accurate clinical decision support tools are needed to allow local doctors to provide expert care. Methods Ariel Dynamic Acute Pancreatitis Tracker (ADAPT) is a digital tool to guide physicians in ordering standard tests, evaluate test results and model progression using available data, propose emergent therapies. The accuracy of the severity score calculators was tested using 2 prospectively ascertained Acute Pancreatitis Patient Registry to Examine Novel Therapies in Clinical Experience cohorts (pilot University of Pittsburgh Medical Center, n = 163; international, n = 1544). Results The ADAPT and post hoc expert-calculated AP severity scores were 100% concordant in both pilot and international cohorts. High-risk criteria of all 4 severity scores at admission were associated with moderately-severe or severe AP and MOF (both P < 0.0001) and prediction of no MOF was 97.8% to 98.9%. The positive predictive value for MOF was 7.5% to 14.9%. Conclusions The ADAPT tool showed 100% accuracy with AP predictive metrics. Prospective evaluation of ADAPT features is needed to determine if additional data can accurately predict and mitigate severe AP and MOF.
- Published
- 2020
34. Guidelines on the histopathology of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and the European Pancreatic Club
- Author
-
Carlos Fernandez-del Castillo, Irene Esposito, Caroline S. Verbeke, Volkan Adsay, Giuseppe Zamboni, Aldo Scarpa, Shuiji Isaji, Lena Haeberle, Andrea Sheel, David C. Whitcomb, Fiona Campbell, Claudio Luchini, Tooru Shimosegawa, John P. Neoptolemos, Benoit Terris, Ashok K. Saluja, Toshio Morohoshi, David S. Klimstra, Ralph H. Hruban, and Koichi Suda
- Subjects
medicine.medical_specialty ,Diagnostic criteria ,Endocrinology, Diabetes and Metabolism ,International Cooperation ,Chronic pancreatitis ,Cytology ,Fibrosis ,Histopathology ,Disease ,Asymptomatic ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Pancreatitis, Chronic ,medicine ,Humans ,Pancreas ,Genetic testing ,Hepatology ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,Evidence-based medicine ,medicine.disease ,030220 oncology & carcinogenesis ,Etiology ,Pancreatitis ,030211 gastroenterology & hepatology ,Differential diagnosis ,medicine.symptom ,business - Abstract
Background Chronic pancreatitis is a complex multifactorial fibro-inflammatory disease. Consensus guidelines are needed for the histopathological evaluation of non-autoimmune chronic pancreatitis (CP). Methods An international working group with experts on the histopathology of CP evaluated 15 statements generated from evidence on seven key clinically relevant questions. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to evaluate the level of evidence available for each statement. To determine the level of agreement, the working group voted on the statements for strength of agreement, using a nine-point Likert scale, and Cronbach’s alpha reliability coefficients were calculated. Results Strong consensus was obtained for 12 statements relating to all seven key questions including that: the cardinal features of CP are the triad of fibrosis, loss of acinar tissue and duct changes; there are no unique histopathological features that distinguish the different aetiologies of CP; clinical history and laboratory investigations, including genetic testing, are important in establishing the aetiology of CP; there is no reproducible and universally accepted histological grading system for assessing severity of CP, although classification as “mild”, “moderate” and “severe” is usually applied; scoring systems for fibrosis are not validated for clinical use; asymptomatic fibrosis is a common finding associated with ageing, and not necessarily evidence of CP; there are no obvious diagnostic macroscopic features of early CP; histopathology is not the gold standard for the diagnosis of CP; and cytology alone is not a reliable method for the diagnosis of CP. Conclusions Cardinal histopathological features of CP are well-defined and internationally accepted and pathological assessment is relevant for the purpose of differential diagnosis with other pancreatic diseases, especially cancer. However, a reliable diagnosis of CP requires integration of clinical, laboratory and imaging features and cannot be made by histology alone.
- Published
- 2020
35. PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies
- Author
-
Sudhir Srivastava, Stephen K. Van Den Eeden, Liang Li, Phil A. Hart, Darwin L. Conwell, Steven J. Hughes, Mohamed O. Othman, Temel Tirkes, Aida Habtezion, Evan L. Fogel, Jose Serrano, Ziding Feng, David C. Whitcomb, Walter G. Park, Stephen J. Pandol, Jo Ann Rinaudo, Chris E. Forsmark, Suresh T. Chari, Mark Topazian, Dhiraj Yadav, Christie Y. Jeon, and William E. Fisher
- Subjects
Adult ,Research design ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Article ,Specimen Handling ,Translational Research, Biomedical ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Pancreatitis, Chronic ,Pancreatic cancer ,Internal medicine ,Outcome Assessment, Health Care ,Diabetes Mellitus ,Internal Medicine ,Humans ,Medicine ,Longitudinal Studies ,Prospective Studies ,Prospective cohort study ,Blood Specimen Collection ,Hepatology ,business.industry ,medicine.disease ,United States ,Pancreatic Neoplasms ,Observational Studies as Topic ,Biorepository ,Research Design ,030220 oncology & carcinogenesis ,Cohort ,Disease Progression ,Pancreatitis ,030211 gastroenterology & hepatology ,business ,Biomarkers ,Cohort study - Abstract
PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and translational stuDies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis in the US. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in chronic pancreatitis. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of chronic pancreatitis - controls, Suspected chronic pancreatitis and Definite chronic pancreatitis. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of chronic pancreatitis. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of chronic pancreatitis.
- Published
- 2018
36. Practice Patterns and Utilization of Tube Feedings in Acute Pancreatitis Patients at a Large US Referral Center
- Author
-
Stephen J OʼKeefe, David C. Whitcomb, Kenneth K.W. Lee, Dhiraj Yadav, Pedram Paragomi, Adam Slivka, Georgios I. Papachristou, Jorge D. Machicado, and Amir Gougol
- Subjects
Adult ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Severity of Illness Index ,Article ,03 medical and health sciences ,Enteral Nutrition ,0302 clinical medicine ,Endocrinology ,Interquartile range ,Internal medicine ,Severity of illness ,Internal Medicine ,Humans ,Medicine ,030212 general & internal medicine ,Practice Patterns, Physicians' ,Referral and Consultation ,Feeding tube ,Aged ,Hepatology ,Practice patterns ,business.industry ,Length of Stay ,Middle Aged ,medicine.disease ,United States ,Clinical trial ,Pancreatitis ,Acute Disease ,Etiology ,Referral center ,Acute pancreatitis ,Female ,030211 gastroenterology & hepatology ,business - Abstract
OBJECTIVES Clinical trials on tube feedings (TFs) have not been sufficiently powered to change practice patterns in acute pancreatitis (AP). We aimed to describe the use, duration, and resource utilization of TF in AP patients at an expert US center. METHODS Of 423 AP patients prospectively enrolled at the University of Pittsburgh Medical Center from 2004 to 2014, 139 (33%) received TF. Data on TF were assessed in 100 (72%) of 139 patients with complete data available. RESULTS Patients on TF were more likely to be male, be obese, have alcohol etiology, and have moderately severe (34% vs 19%) or severe AP (62% vs. 3%) (P < 0.05). Tube feedings were started after a median of 5 days (interquartile range, 3-8 days) from admission and were administered for a median of 39 days (interquartile range, 19-58 days). A nasojejunal route (95%) with an oligomeric formula (92%) was the preferred TF strategy. Feeding tube complications led to at least 1 endoscopic tube replacement in 42% of patients and to an unexpected health care visit in 29% of those discharged on TF (16/55 patients). CONCLUSIONS Tube feedings form an important component in the management of patients with moderately severe and severe AP. Further studies should define the optimal utilization of TF and ways to reduce TF-related complications.
- Published
- 2018
37. Guidelines for the Diagnostic Cross Sectional Imaging and Severity Scoring of Chronic Pancreatitis
- Author
-
John P. Neoptolemos, Ingfrid S. Haldorsen, Jens Brøndum Frøkjær, Burcu Akpinar, Fatih Akisik, David C. Whitcomb, Andrea Sheel, Ammad Farooq, Asbjørn Mohr Drewes, Maria Chiara Petrone, Søren Schou Olesen, Anil K. Dasyam, Tooru Shimosoegawa, and Giovanni Morana
- Subjects
Endoscopic ultrasound ,medicine.medical_specialty ,Internationality ,Endocrinology, Diabetes and Metabolism ,Guidelines ,Severity ,Imaging ,Cross-sectional imaging ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Fibrosis ,Pancreatitis, Chronic ,Diagnosis ,medicine ,Humans ,Stage (cooking) ,Pathological ,Hepatology ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,Magnetic resonance imaging ,medicine.disease ,Magnetic Resonance Imaging ,030220 oncology & carcinogenesis ,Radiological weapon ,Practice Guidelines as Topic ,Pancreatitis ,030211 gastroenterology & hepatology ,Radiology ,Tomography, X-Ray Computed ,business ,Chronic pancreatitis - Abstract
The paper presents the international guidelines for imaging evaluation of chronic pancreatitis. The following consensus was obtained: Computed tomography (CT) is often the most appropriate initial imaging modality for evaluation of patients with suspected chronic pancreatitis (CP) depicting most changes in pancreatic morphology. CT is also indicated to exclude other potential intraabdominal pathologies presenting with symptoms similar to CP. However, CT cannot exclude a diagnosis of CP nor can it be used to exclusively diagnose early or mild disease. Here magnetic resonance imaging (MRI) and MR cholangiopancreatography (MRCP) is superior and is indicated especially in patients where no specific pathological changes are seen on CT. Secretin-stimulated MRCP is more accurate than standard MRCP in the depiction of subtle ductal changes. It should be performed after a negative MRCP, when there is still clinical suspicion of CP. Endoscopic ultrasound (EUS) can also be used to diagnose parenchymal and ductal changes mainly during the early stage of the disease. No validated radiological severity scoring systems for CP are available, although a modified Cambridge Classification has been used for MRCP. There is an unmet need for development of a new and validated radiological CP severity scoring system based on imaging criteria including glandular volume loss, ductal changes, parenchymal calcifications and parenchymal fibrosis based on CT and/or MRI. Secretin-stimulated MRCP in addition, can provide assessment of exocrine function and ductal compliance. An algorithm is presented, where these imaging parameters can be incorporated together with clinical findings in the classification and severity grading of CP.
- Published
- 2018
38. Known genetic susceptibility factors for chronic pancreatitis in patients of European ancestry are rare in patients of African ancestry
- Author
-
Stuart Sherman, Samer Alkaade, Michelle A. Anderson, Jessica LaRusch, Thiruvengadam Muniraj, Phil J. Greer, Vikesh K. Singh, C. Mel Wilcox, Chris E. Forsmark, Andres Gelrud, John Baillie, Darwin L. Conwell, Michele D. Lewis, Dhiraj Yadav, Mary E. Money, Nalini M. Guda, Judah Abberbock, Anna E. Phillips, Stephen T. Amann, David C Whitcomb, Gregory A. Cote, Adam Slivka, Randall E. Brand, Timothy B. Gardner, Bimaljit S. Sandhu, Gong Tang, and Peter A. Banks
- Subjects
0301 basic medicine ,African american ,medicine.medical_specialty ,Hepatology ,business.industry ,Endocrinology, Diabetes and Metabolism ,Gastroenterology ,Genetic variants ,Recurrent acute pancreatitis ,medicine.disease ,Article ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Internal medicine ,Genetic variation ,Genetic predisposition ,medicine ,Pancreatitis ,030211 gastroenterology & hepatology ,In patient ,business ,Genotyping - Abstract
BACKGROUND: Multiple pathogenic genetic variants are associated with pancreatitis in patients of European (EA) and Asian ancestries, but studies on patients of African ancestry (AA) are lacking. We evaluated the prevalence of known genetic variations in African-American subjects in the US. METHODS: We studied prospectively enrolled controls (n = 238) and patients with chronic (CP) (n = 232) or recurrent acute pancreatitis (RAP) (n = 45) in the NAPS2 studies from 2000–2014 of self-identified AA. Demographic and phenotypic information was obtained from structured questionnaires. Ancestry and admixture were evaluated by principal component analysis (PCA). Genotyping was performed for pathogenic genetic variants in PRSS1, SPINK1, CFTR and CTRC. Prevalence of disease-associated variants in NAPS2 subjects of AA and EA was compared. RESULTS: When compared with CP subjects of EA (n = 862), prevalence of established pathogenic genetic variants was infrequent in AA patients with CP, overall (29 vs. 8.19%, OR 4.60, 95% CI 2.74–7.74, p < 0.001), and after stratification by alcohol etiology (p < 0.001). On PCA, AA cases were more heterogeneous but distinct from EA subjects; no difference was observed between AA subjects with and without CP-associated variants. Of 19 A A patients with CP who had pathogenic genetic variants, 2 had variants in PRSS1 (R122H, R122C), 4 in SPINK1 (all N34S heterozygotes), 12 in CFTR (2 CFTR(sev), 9 CFTR(BD), 1 compound heterozygote with CFTR(sev) and CFTR(BD)), and 1 in CTRC (R254W). CONCLUSION: Pathogenic genetic variants reported in EA patients are significantly less common in AA patients. Further studies are needed to determine the complex risk factors for AA subjects with pancreatitis.
- Published
- 2018
39. Overweight or Obese Individuals at Eighteen Years of Age Develop Pancreatic Adenocarcinoma at a Significantly Earlier Age
- Author
-
Herbert J. Zeh, David C. Whitcomb, Nathan Bahary, Randall E. Brand, Kevin McGrath, Amer H. Zureikat, Aatur D. Singhi, Nilesh Shah, Kenneth E. Fasanella, and David T. Chao
- Subjects
medicine.medical_specialty ,Article Subject ,Overweight ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,lcsh:RC799-869 ,10. No inequality ,2. Zero hunger ,Retrospective review ,Hepatology ,business.industry ,Significant difference ,Gastroenterology ,nutritional and metabolic diseases ,Mean age ,Adolescent Obesity ,medicine.disease ,3. Good health ,030220 oncology & carcinogenesis ,Adenocarcinoma ,lcsh:Diseases of the digestive system. Gastroenterology ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,Body mass index ,Research Article - Abstract
Background. Adolescent obesity is a national epidemic that recently has been shown to increase risk for pancreatic adenocarcinoma (PC) and is associated with an earlier age of PC onset. We hypothesized that PC patients who are overweight or obese at age 18 would have an earlier age of PC onset. Methods. Retrospective review of 531 patients in our PC registry was completed. Self-reported weight at age 18 and maximum lifetime weight were used to calculate body mass index (BMI) at age 18 (BMI-18) and maximum lifetime BMI. Results. Complete BMI and baseline covariate data was available in 319 PC patients. Mean age (in years) of PC diagnosis for patients whose BMI-18 was overweight (64.0) or obese (59.9) was significantly different when compared to patients with a normal BMI-18 (66.7). No significant difference was observed in the mean age of PC diagnosis in those patients who maintained a normal BMI-18 when compared to those patients who subsequently became overweight or obese (67.0 versus 66.6; p=0.65). Conclusions. An elevated BMI at age 18 is associated with an earlier age of PC onset and should be factored into determining the optimal age of beginning screening for patients at high risk for PC.
- Published
- 2018
40. The −251 A/T Polymorphism in the IL8 Promoter is a Risk Factor for Acute Pancreatitis
- Author
-
Kimberly Stello, Nijole Pollock, Anna C. Evans, Rawad Mounzer, Shrinivas Bishu, Georgios I. Papachristou, Efstratios Koutroumpakis, and David C. Whitcomb
- Subjects
Adult ,Male ,medicine.medical_specialty ,Genotype ,Endocrinology, Diabetes and Metabolism ,Inflammation ,Polymorphism, Single Nucleotide ,Gastroenterology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Gene Frequency ,Risk Factors ,Internal medicine ,Internal Medicine ,medicine ,Genetic predisposition ,Humans ,Genetic Predisposition to Disease ,Prospective Studies ,Interleukin 8 ,Promoter Regions, Genetic ,Alleles ,Aged ,Hepatology ,business.industry ,Interleukin-8 ,Interleukin ,Odds ratio ,Middle Aged ,medicine.disease ,Real-time polymerase chain reaction ,Pancreatitis ,030220 oncology & carcinogenesis ,Acute Disease ,Acute pancreatitis ,Female ,030211 gastroenterology & hepatology ,medicine.symptom ,business - Abstract
Objectives Inflammation in the setting of acute pancreatitis (AP) is partially driven by pathogen recognition receptors that recognize damage-associated molecular patterns. Interleukin (IL)-8 is a chemotactic factor produced by pathogen recognition receptor-expressing cells. A single-nucleotide polymorphism in IL8 promoter region (-251 A/T) has been implicated in inflammatory diseases. We examined whether this IL8 polymorphism confers susceptibility to AP. Methods Patients with AP (n = 357) were prospectively recruited. Clinical data and blood were collected in subjects and controls (n = 347). Severity was defined following the Revised Atlanta Classification. Genotypes were assessed by quantitative polymerase chain reaction using TaqMan probes. Results Patients and controls had similar demographics and had no difference in Hardy-Weinberg (patients, P = 0.29; controls, P = 0.66). Twenty-five percent of patients developed severe AP. Compared with controls, the A/A genotype was more common in AP (P = 0.041; odds ratio, 1.42; 95% confidence interval, 1-1.99). Obese patients with the A/A genotype were more likely to develop mild AP (P = 0.047). Conclusions The -251 polymorphism confers susceptibility to AP and disease severity in obese patients. However, its effect is moderate. One potential mechanism for this susceptibility is via increased IL8 production by innate cells, with subsequent enhanced neutrophil influx and pancreatic injury.
- Published
- 2018
41. S43 Characterizing Unmet Needs in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis: A Patient-Centered Observational Approach
- Author
-
Nathalie Erpelding, Rahul Pannala, Yasmin G. Hernandez-Barco, Trudi Delk, Caryl Kahn, David C. Whitcomb, Jodie A. Barkin, Abbe Steel, and Dennis L. Decktor
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,medicine.disease ,Unmet needs ,medicine ,Pancreatitis ,In patient ,Observational study ,Exocrine pancreatic insufficiency ,Intensive care medicine ,business ,Patient centered - Published
- 2021
42. Patient and Disease Characteristics Associated With the Presence of Diabetes Mellitus in Adults With Chronic Pancreatitis in the United States
- Author
-
Gregory A. Cote, Samer Alkaade, Adam Slivka, Michele D. Lewis, Randall E. Brand, Michelle A. Anderson, Peter A. Banks, Stephen T. Amann, David C. Whitcomb, Thiruvengadam Muniraj, Stuart Sherman, Timothy B. Gardner, Nalini M. Guda, John Baillie, Bimaljit S. Sandhu, Andres Gelrud, Gong Tang, Chris E. Forsmark, Judah Abberbock, Melena D. Bellin, Darwin L. Conwell, Dhiraj Yadav, C. Mel Wilcox, and Vikesh K. Singh
- Subjects
Adult ,Male ,medicine.medical_specialty ,endocrine system diseases ,Cross-sectional study ,Type 2 diabetes ,Overweight ,Article ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Pancreatitis, Chronic ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,Obesity ,Prospective Studies ,Prospective cohort study ,Hepatology ,business.industry ,Gastroenterology ,Middle Aged ,medicine.disease ,United States ,Surgery ,Cross-Sectional Studies ,Diabetes Mellitus, Type 2 ,030220 oncology & carcinogenesis ,Pancreatitis ,Female ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,Cohort study - Abstract
Diabetes mellitus (DM) is a common complication of chronic pancreatitis (CP). Past studies for DM risk factors in CP have been limited to single centers or highly focused on a single etiology such as alcoholic or hereditary disease. We studied risk factors for DM in a large population of patients with CP of all etiologies enrolled in the North American Pancreatitis 2 studies.Participants (1,171) with CP (n=383 with DM, n=788 without DM) were enrolled prospectively from 26 participating centers. Questionnaires were completed by patients and physicians in a cross-sectional assessment. Patient demographics and disease characteristics were compared for CP with DM vs. without DM. Logistic regression was performed to assess the variables associated with DM diagnosis in a multivariable model.Diabetics were more likely to be black (P=0.02), overweight, or obese (P0.001), and with a family history of DM (P=0.0005). CP patients with DM were more likely to have pancreatic calcifications (63% vs. 54%, P=0.002), atrophy (44% vs. 32%, P0.0001), and prior pancreas surgery (26.9% vs. 16.9%, P0.0001). In multivariate logistic regression modeling, the strongest risk factors for DM were obesity (odds ratio (OR) 2.8, 95% confidence interval (CI) 1.9, 4.2) and exocrine insufficiency (OR 2.4, 95% CI 1.8, 3.2).In this large multicenter cohort of patients with CP, exocrine insufficiency, calcifications, and pancreas surgery conveyed higher odds of having DM. However, the traditional 'type 2 DM' risk factors of obesity and family history were similarly important in conveying risk for DM.
- Published
- 2017
43. Clinical outcomes of isolated renal failure compared to other forms of organ failure in patients with severe acute pancreatitis
- Author
-
David C. Whitcomb, Phil J. Greer, Adam Slivka, Mohannad Dugum, Georgios I. Papachristou, Amir Gougol, Dhiraj Yadav, and Anwar Dudekula
- Subjects
Male ,Necrosis ,Comorbidity ,Respiratory failure ,Tertiary Care Centers ,0302 clinical medicine ,Clinical outcomes ,Organ failure ,Prospective Studies ,Renal Insufficiency ,Prospective cohort study ,APACHE ,Nutritional Support ,Gastroenterology ,General Medicine ,Middle Aged ,Prognosis ,Intensive Care Units ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Acute pancreatitis ,030211 gastroenterology & hepatology ,Female ,medicine.symptom ,Pancreas ,Risk assessment ,Respiratory Insufficiency ,Adult ,medicine.medical_specialty ,Renal failure ,Multiple Organ Failure ,macromolecular substances ,Risk Assessment ,03 medical and health sciences ,medicine ,Humans ,Intensive care medicine ,Aged ,business.industry ,Length of Stay ,medicine.disease ,Pancreatitis ,Prospective Study ,business - Abstract
AIM To assess differences in clinical outcomes of isolated renal failure (RF) compared to other forms of organ failure (OF) in patients with severe acute pancreatitis (SAP). METHODS Using a prospectively maintained database of patients with acute pancreatitis admitted to a tertiary medical center between 2003 and 2016, those with evidence of persistent OF were classified to renal, respiratory, cardiovascular, or multi-organ (2 or more organs). Data regarding demographics, comorbidities, etiology of acute pancreatitis, and clinical outcomes were prospectively recorded. Differences in clinical outcomes after development of isolated RF in comparison to other forms of OF were determined using independent t and Mann-Whitney U tests for continues variables, and χ2 test for discrete variables. RESULTS Among 500 patients with acute pancreatitis, 111 patients developed persistent OF: mean age was 54 years, and 75 (67.6%) were male. Forty-three patients had isolated OF: 17 (15.3%) renal, 25 (21.6%) respiratory, and 1 (0.9%) patient with cardiovascular failure. No differences in demographics, etiology of acute pancreatitis, systemic inflammatory response syndrome scores, or development of pancreatic necrosis were seen between patients with isolated RF vs isolated respiratory failure. Patients with isolated RF were less likely to require nutritional support (76.5% vs 96%, P = 0.001), ICU admission (58.8% vs 100%, P = 0.001), and had shorter mean ICU stay (2.4 d vs 15.7 d, P < 0.001), compared to isolated respiratory failure. None of the patients with isolated RF or isolated respiratory failure died. CONCLUSION Among patients with SAP per the Revised Atlanta Classification, approximately 15% develop isolated RF. This subgroup seems to have a less protracted clinical course compared to other forms of OF. Isolated RF might be weighed less than isolated respiratory failure in risk predictive modeling of acute pancreatitis.
- Published
- 2017
44. An international multicenter study of early intravenous fluid administration and outcome in acute pancreatitis
- Author
-
Claudia Sánchez-Marin, Georgios I. Papachristou, Efstratios Koutroumpakis, Vikesh K. Singh, Timothy B. Gardner, Amitasha Sinha, Nikhil Seth, Elham Afghani, Mahya Faghih, Noé Quesada-Vázquez, Félix Lluís, Enrique de-Madaria, Nelly G. Acevedo-Piedra, Mónica Rey-Riveiro, Pedro Zapater, Neftalí Moya-Hoyo, David C. Whitcomb, and Juan José Martínez
- Subjects
Resuscitation ,medicine.medical_specialty ,business.industry ,Gastroenterology ,Retrospective cohort study ,Original Articles ,Odds ratio ,medicine.disease ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Intravenous fluid ,Oncology ,Multicenter study ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Acute pancreatitis ,030211 gastroenterology & hepatology ,In patient ,business ,Fluid volume - Abstract
Early aggressive fluid resuscitation in acute pancreatitis is frequently recommended but its benefits remain unproven. The aim of this study was to determine the outcomes associated with early fluid volume administration in the emergency room (FVER) in patients with acute pancreatitis.A four-center retrospective cohort study of 1010 patients with acute pancreatitis was conducted. FVER was defined as any fluid administered from the time of arrival to the emergency room to 4 h after diagnosis of acute pancreatitis, and was divided into tertiles: nonaggressive (500 ml), moderate (500 to 1000 ml), and aggressive (1000 ml).Two hundred sixty-nine (26.6%), 427 (42.3%), and 314 (31.1%) patients received nonaggressive, moderate, and aggressive FVER respectively. Compared with the nonaggressive fluid group, the moderate group was associated with lower rates of local complications in univariable analysis, and interventions, both in univariable and multivariable analysis (adjusted odds ratio (95% confidence interval): 0.37 (0.14-0.98)). The aggressive resuscitation group was associated with a significantly lower need for interventions, both in univariable and multivariable analysis (adjusted odds ratio 0.21 (0.05-0.84)). Increasing fluid administration categories were associated with decreasing hospital stay in univariable analysis.Early moderate to aggressive FVER was associated with lower need for invasive interventions.
- Published
- 2017
45. Academic Pancreas Centers of Excellence: Guidance from a multidisciplinary chronic pancreatitis working group at PancreasFest
- Author
-
Linda S. Lee, Randall E. Brand, Sunil A Sheth, Matthew Alsante, Steven D. Freedman, Phil A. Hart, Stephen J. Pandol, C. Mel Wilcox, Fred S. Gorelick, Andres Gelrud, Michelle A. Anderson, Vikesh K. Singh, Darwin L. Conwell, Katherine A. Morgan, Gregory A. Cote, Jamie S. Barkin, David C Whitcomb, and Dhiraj Yadav
- Subjects
medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,media_common.quotation_subject ,Center of excellence ,education ,Guidelines as Topic ,Disease ,Article ,03 medical and health sciences ,0302 clinical medicine ,Multidisciplinary approach ,Excellence ,Pancreatitis, Chronic ,Epidemiology ,medicine ,Humans ,Intensive care medicine ,Pancreas ,media_common ,Patient Care Team ,Hepatology ,business.industry ,Gastroenterology ,medicine.disease ,Deliberation ,Pancreatic Function Tests ,Conceptual framework ,030220 oncology & carcinogenesis ,Pancreatitis ,030211 gastroenterology & hepatology ,business - Abstract
Chronic pancreatitis (CP) is a progressive inflammatory disease, which leads to loss of pancreatic function and other disease-related morbidities. A group of academic physicians and scientists developed comprehensive guidance statements regarding the management of CP that include its epidemiology, diagnosis, medical treatment, surgical treatment, and screening. The statements were developed through literature review, deliberation, and consensus opinion. These statements were ultimately used to develop a conceptual framework for the multidisciplinary management of chronic pancreatitis referred to as an academic pancreas center of excellence (APCOE).
- Published
- 2017
46. Quality of Life in Chronic Pancreatitis is Determined by Constant Pain, Disability/Unemployment, Current Smoking, and Associated Co-Morbidities
- Author
-
Timothy B. Gardner, Judah Abberbock, Michelle A. Anderson, Nalini M. Guda, Samer Alkaade, Chris E. Forsmark, Peter A. Banks, Stephen T. Amann, Bimaljit S. Sandhu, Randall E. Brand, Gregory A. Cote, Stuart Sherman, Adam Slivka, John Baillie, Vikesh K. Singh, Jorge D. Machicado, Thiruvengadam Muniraj, David C. Whitcomb, Darwin L. Conwell, Andres Gelrud, Gong Tang, Michele D. Lewis, Dhiraj Yadav, and C. Mel Wilcox
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Abdominal pain ,Time Factors ,media_common.quotation_subject ,Comorbidity ,Article ,03 medical and health sciences ,Sex Factors ,0302 clinical medicine ,Quality of life (healthcare) ,Pancreatitis, Chronic ,Surveys and Questionnaires ,Diabetes mellitus ,Diabetes Mellitus ,Humans ,Medicine ,Exocrine pancreatic insufficiency ,Pain Measurement ,media_common ,Hepatology ,business.industry ,Smoking ,Gastroenterology ,Middle Aged ,medicine.disease ,Abdominal Pain ,Unemployment ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Sick leave ,Linear Models ,Quality of Life ,Physical therapy ,Pancreatitis ,Exocrine Pancreatic Insufficiency ,Female ,030211 gastroenterology & hepatology ,Sick Leave ,medicine.symptom ,business - Abstract
Chronic pancreatitis (CP) has a profound independent effect on quality of life (QOL). Our aim was to identify factors that impact the QOL in CP patients.We used data on 1,024 CP patients enrolled in the three NAPS2 studies. Information on demographics, risk factors, co-morbidities, disease phenotype, and treatments was obtained from responses to structured questionnaires. Physical and mental component summary (PCS and MCS, respectively) scores generated using responses to the Short Form-12 (SF-12) survey were used to assess QOL at enrollment. Multivariable linear regression models determined independent predictors of QOL.Mean PCS and MCS scores were 36.7±11.7 and 42.4±12.2, respectively. Significant (P0.05) negative impact on PCS scores in multivariable analyses was noted owing to constant mild-moderate pain with episodes of severe pain or constant severe pain (10 points), constant mild-moderate pain (5.2), pain-related disability/unemployment (5.1), current smoking (2.9 points), and medical co-morbidities. Significant (P0.05) negative impact on MCS scores was related to constant pain irrespective of severity (6.8-6.9 points), current smoking (3.9 points), and pain-related disability/unemployment (2.4 points). In women, disability/unemployment resulted in an additional 3.7 point reduction in MCS score. Final multivariable models explained 27% and 18% of the variance in PCS and MCS scores, respectively. Etiology, disease duration, pancreatic morphology, diabetes, exocrine insufficiency, and prior endotherapy/pancreatic surgery had no significant independent effect on QOL.Constant pain, pain-related disability/unemployment, current smoking, and concurrent co-morbidities significantly affect the QOL in CP. Further research is needed to identify factors impacting QOL not explained by our analyses.
- Published
- 2017
47. Prevalence and Associated Factors of Abdominal Pain and Disability at 1-Year Follow-up After an Attack of Acute Pancreatitis
- Author
-
Ioannis Pothoulakis, Dhiraj Yadav, David C. Whitcomb, Pedram Paragomi, Georgios I. Papachristou, Bassem Matta, Jorge D. Machicado, Adam Slivka, and Amir Gougol
- Subjects
Adult ,Male ,medicine.medical_specialty ,Abdominal pain ,Activities of daily living ,Endocrinology, Diabetes and Metabolism ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,law ,Internal medicine ,Activities of Daily Living ,Internal Medicine ,Prevalence ,Medicine ,Humans ,Prospective Studies ,Aged ,Hepatology ,business.industry ,Odds ratio ,Middle Aged ,medicine.disease ,Intensive care unit ,Confidence interval ,Abdominal Pain ,Pancreatitis ,030220 oncology & carcinogenesis ,Etiology ,Acute pancreatitis ,030211 gastroenterology & hepatology ,Female ,medicine.symptom ,business ,Follow-Up Studies - Abstract
OBJECTIVE The aim of the study was to report the prevalence and predictors of abdominal pain and disability 1 year after an acute pancreatitis (AP) attack. METHODS Patients were prospectively enrolled between December 2012 and April 2016. Enrolled subjects were contacted at a median of 13 months after enrollment. Multivariable regression models were used to determine factors independently associated with abdominal pain at follow-up. RESULTS Response rate was 71% (110/155). Of respondents, median age was 51 years, 58% were female, and 14% had severe AP. At follow-up, 24% of patients reported abdominal pain (65% intermittent, 35% constant), 10% used analgesics regularly, and 6% had regular opioids use. Furthermore, 41% of patients experienced pain-related interference with work or daily activities, and 8% developed disability. On regression analysis, idiopathic etiology (odds ratio [OR], 3.8; 95% confidence interval [CI], 1.1-13.6) persistent organ failure (OR, 3.3; 95% CI, 1.1-7.9), and recurrent AP (OR, 2.9; 95% CI, 1.1-10.6) were independently associated with abdominal pain at follow-up. Disability at follow-up was associated with younger age, current smoking, and intensive care unit admission (all P < 0.05). CONCLUSIONS Abdominal pain and disability are potential long-term sequelae of AP. Certain pre-existing factors and pancreatitis features are associated with these outcomes at one-year follow-up of AP.
- Published
- 2019
48. The role of total pancreatectomy with islet autotransplantation in the treatment of chronic pancreatitis: A report from the International Consensus Guidelines in chronic pancreatitis
- Author
-
Takayuki Anazawa, Helmut Friess, Jaimie D. Nathan, Marlon F. Levy, Martin L. Freeman, Andrea Sheel, John P. Neoptolemos, Ihsan Ekin Demir, John A. Windsor, Marc G. Besselink, Jens Werner, Marco Del Chiaro, David C. Whitcomb, Johanna Laukkarinen, Melena D. Bellin, Gregory J. Beilman, Tooru Shimosegawa, Maisam Abu-El-Haija, Ashley R. Dennison, Thilo Hackert, Vikas Dudeja, Jörg Kleeff, Surgery, AGEM - Digestive immunity, and AGEM - Re-generation and cancer of the digestive system
- Subjects
medicine.medical_specialty ,Internationality ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Islets of Langerhans Transplantation ,Disease ,03 medical and health sciences ,Islets of Langerhans ,0302 clinical medicine ,Pancreatectomy ,Quality of life ,Diabetes mellitus ,Pancreatitis, Chronic ,medicine ,Humans ,Intensive care medicine ,Glycemic ,geography ,geography.geographical_feature_category ,Hepatology ,business.industry ,TPIAT ,Diabetes ,Gastroenterology ,medicine.disease ,Islet ,Autotransplantation ,Autoislet ,Pancreatitis ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,030211 gastroenterology & hepatology ,business - Abstract
Background Advances in our understanding of total pancreatectomy with islet autotransplantation (TPIAT) have been made. We aimed to define indications and outcomes of TPIAT. Methods Expert physician-scientists from North America, Asia, and Europe reviewed the literature to address six questions selected by the writing group as high priority topics. A consensus was reached by voting on statements generated from the review. Results Consensus statements were voted upon with strong agreement reached that (Q1) TPIAT may improve quality of life, reduce pain and opioid use, and potentially reduce medical utilization; that (Q3) TPIAT offers glycemic benefit over TP alone; that (Q4) the main indication for TPIAT is disabling pain, in the absence of certain medical and psychological contraindications; and that (Q6) islet mass transplanted and other disease features may impact diabetes mellitus outcomes. Conditional agreement was reached that (Q2) the role of TPIAT for all forms of CP is not yet identified and that head-to-head comparative studies are lacking, and that (Q5) early surgery is likely to improve outcomes as compared to late surgery. Conclusions Agreement on TPIAT indications and outcomes has been reached through this working group. Further studies are needed to answer the long-term outcomes and maximize efforts to optimize patient selection.
- Published
- 2019
49. International consensus guidelines for surgery and the timing of intervention in chronic pancreatitis
- Author
-
Jörg Kleeff, Andrea Sheel, David C. Whitcomb, U. Ahmed Ali, Ryan Baron, Yama Issa, Marinus A. Kempeneers, John A. Windsor, Johanna Laukkarinen, C. Fernandez-del Castillo, J. R. Izbicki, Marc G. Besselink, S. Isaji, M.W. Büchler, Mert Erkan, Y. Miao, Toru Shimosegawa, John P. Neoptolemos, and Marja A. Boermeester
- Subjects
medicine.medical_specialty ,Consensus ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Pancreaticoduodenectomy ,Time-to-Treatment ,03 medical and health sciences ,0302 clinical medicine ,Pancreatectomy ,Risk Factors ,Pancreatic cancer ,Pancreaticojejunostomy ,Pancreatitis, Chronic ,medicine ,Humans ,Hepatology ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,Definition ,Evidence-based medicine ,Guideline ,Classification ,medicine.disease ,Prophylactic Surgery ,Surgery ,Endoscopy ,Pain, Intractable ,Treatment ,030220 oncology & carcinogenesis ,Pancreatitis ,030211 gastroenterology & hepatology ,Intractable pain ,Pancreatic Cyst ,business - Abstract
Background/objectives Chronic pancreatitis (CP) is a complex inflammatory disease with pain as the predominant symptom. Pain relief can be achieved using invasive interventions such as endoscopy and surgery. This paper is part of the international consensus guidelines on CP and presents the consensus guideline for surgery and timing of intervention in CP. Methods An international working group with 15 experts on CP surgery from the major pancreas societies (IAP, APA, JPS, and EPC) evaluated 20 statements generated from evidence on 5 questions deemed to be the most clinically relevant in CP. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to evaluate the level of evidence available for each statement. To determine the level of agreement, the working group voted on the 20 statements for strength of agreement, using a nine-point Likert scale in order to calculate Cronbach’s alpha reliability coefficient. Results Strong consensus was obtained for the following statements: Surgery in CP is indicated as treatment of intractable pain and local complications of adjacent organs, and in case of suspicion of malignant (cystic) lesion; Early surgery is favored over surgery in a more advanced stage of disease to achieve optimal long-term pain relief; In patients with an enlarged pancreatic head, a combined drainage and resection procedure, such as the Frey, Beger, and Berne procedure, may be the treatment of choice; Pancreaticoduodenectomy is the most suitable surgical option for patients with groove pancreatitis; The risk of pancreatic carcinoma in patients with CP is too low (2% in 10 year) to recommend active screening or prophylactic surgery; Patients with hereditary CP have such a high risk of pancreatic cancer that prophylactic resection can be considered (lifetime risk of 40–55%). Weak agreement for procedure choice in patients with dilated duct and normal size pancreatic head: both the extended lateral pancreaticojejunostomy and Frey procedure seems to provide equivalent pain control in patients. Conclusions This international expert consensus guideline provides evidenced-based statements concerning key aspects in surgery and timing of intervention in CP. It is meant to guide clinical practitioners and surgeons in the treatment of patients with CP.
- Published
- 2019
50. Cystic fibrosis transmembrane conductance regulator modulators reduce the risk of recurrent acute pancreatitis among adult patients with pancreas sufficient cystic fibrosis
- Author
-
Mark T. Jennings, Vikesh K. Singh, Christian A. Merlo, Natalie E. West, Mahya Faghih, Ayesha Kamal, Noah Lechtzin, Liudmila Cebotaru, Venkata S. Akshintala, Rebecca Dezube, David C. Whitcomb, and Garry R. Cutting
- Subjects
Adult ,Male ,medicine.medical_specialty ,Abdominal pain ,Indoles ,Cystic Fibrosis ,Endocrinology, Diabetes and Metabolism ,Aminopyridines ,Cystic Fibrosis Transmembrane Conductance Regulator ,Quinolones ,Aminophenols ,Gastroenterology ,Cystic fibrosis ,Ivacaftor ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Benzodioxoles ,Aged ,Retrospective Studies ,Hepatology ,biology ,business.industry ,Lumacaftor ,Middle Aged ,medicine.disease ,Cystic fibrosis transmembrane conductance regulator ,medicine.anatomical_structure ,chemistry ,030220 oncology & carcinogenesis ,biology.protein ,Acute pancreatitis ,Pancreatitis ,030211 gastroenterology & hepatology ,Exocrine Pancreatic Insufficiency ,Female ,medicine.symptom ,Pancreas ,business ,medicine.drug - Abstract
Background Approximately 1 in 5 patients with pancreas sufficient cystic fibrosis (PS-CF) will develop acute pancreatitis (AP). It is not known whether ivacaftor alone or in combination with other CFTR (cystic transmembrane regulator) modulators (tezacaftor or lumacaftor) can reduce the risk of AP in patients with PS-CF and AP history. Methods We retrospectively queried the CF registry at our institution for adult patients with PS-CF, a documented history of AP and initiation of CFTR modulators for pulmonary indications. Patient characteristics including demographics, CFTR genotype, pancreatitis risk factors, pancreatic exocrine function and other relevant laboratory, imaging parameters were obtained from the time of the sentinel AP episode through the follow-up period. Results A total of 15 adult CF patients were identified with mean age of 44.1 years (SD ± 13.8). In the 24 months preceding CFTR modulator initiation, six of these patients had at least 1 episode of AP with median of 2 episodes [1.75, 2.5]. None of the patients had evidence of pancreatic calcifications or exocrine pancreas insufficiency at the time of CFTR modulator initiation. The mean duration of follow-up after CFTR modulator initiation was 36.7 months (SD ± 21.5). None of the patients who remained on CFTR modulators developed an episode of AP or required hospitalization for AP related abdominal pain during follow-up. Conclusions CFTR modulators, alone or in combination, substantially reduce the risk of recurrent AP over a mean follow-up period of 3 years in adult patients with PS-CF and a history of prior AP. These data suggest that any augmentation of CFTR function can reduce the risk of pancreatitis.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.